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Neuropathic pain results from damage to peripheral sensory axons, which 
can occur due to physical trauma (via nerve trauma) or metabolic diseases (via 
diabetes). Neuropathic pain can be a debilitating disease that often responds 
poorly from pharmacological interventions. The ability of exercise to reduce 
behavioral sensitivity associated with neuropathic pain in rodents has been 
reported; however, the exercise-induced mechanisms were not researched in 
this study. Increases in neurotrophic factors (e.g. glial cell line-derived 
neurotrophic factor [GDNF]) have been proposed as a possible mechanism for 
reducing neuropathic pain. Therefore, the purpose of this study is to determine 
whether voluntary exercise can attenuate or delayed mechanical sensitivity 
associated with neuropathic pain and assess GDNF levels as a possible 
mechanism. Two neuropathic pain models (SNI and streptozotocin [STZ]-
induced diabetes [type 1 model]) were assessed. Following surgery and/or 
injections, animals in the exercised groups were housed in standard cages with 
voluntary running wheels while the sedentary group was housed without wheels. 
To quantify neuropathic pain mechanical allodynia and hyperalgesia were 
assessed. GDNF protein levels and mRNA expression were examined in the 
lumbar region of the spinal cord, dorsal root ganglion (DRG), sciatic nerve, and 
skeletal muscle. Our results showed that both models produced mechanical 
hypersensitivity. However, voluntary exercise significantly reduced mechanical 
hypersensitivity within 2 to 3 weeks. Within the spinal cord, the SNI surgery 
increased GDNF protein levels, whereas diabetes significantly decreased GDNF 
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levels. Voluntary exercise had no effect on GDNF levels after nerve injury; 
however, among diabetic animals voluntary exercise significantly increased 
GDNF protein levels in the spinal cord and sciatic nerve, mRNA expression in 
skeletal muscle, along with axonal transport in the sciatic nerve. Intrathecal 
injections of recombinant GDNF ameliorated mechanical sensitivity associated 
with diabetic neuropathy, therefore implicating the potential therapeutic actions of 
GDNF. In summary, voluntary exercise caused favorable changes in behavioral 
sensitivity in both nerve-injured and diabetic rodents. In diabetic rodents this 
reduction in mechanical sensitivity may be due to an increase in GDNF and 
axonal transport, whereas the exercise-induced mechanism after nerve injury 
remains unknown. This investigation supports the use of exercise to complement 
current treatment strategies aimed at decreasing neuropathic pain associated 
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1.1.1 Epidemiology of pain 
Pain, whether acute or chronic, is the most common reason for health 
care visits [1]. It has been estimated that pain related symptoms account for 1 in 
6 visits to a healthcare provider costing upwards to $100 billion. Estimates are 
that 25 million Americans experience acute pain; with another 50 million suffering 
from chronic pain. Pain not only affects the patient but also their family, society, 
and the economy. It is estimated that 36 million Americans affected by pain miss 
nearly 4 billion work days resulting in an extensive loss of work and productivity 
at an estimated cost of $65 billion per year [2]. Despite its prevalence, currently 
there is no treatment to prevent the development or adequately control pain [3-5]. 
 
Pain is defined as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage” [6]. Pain is classified as either nociceptive or neuropathic. Nociceptive 
pain is elicited by a noxious stimulation (mechanical, chemical, or thermal) of the 
peripheral sensory nerves, whereas, neuropathic pain arises from injury or 
disease of neurons in the peripheral (PNS) or central nervous system (CNS) [7, 
8]. The ability to experience pain has a protective role. It warns of any potential or 
actual tissue damage, which therefore elicits a reflexive response to minimize the 
chances of damage from occurring, however, neuropathic pain offers no known 




1.1.2 Nociceptors, the pain pathway, and mechanisms of pain 
Nociceptors are primary sensory neurons that specialize in detecting 
intense thermal, mechanical, or chemical stimuli. There are two major classes of 
nociceptors: 1) A-delta (Aδ), which are medium diameter myelinated afferents 
that mediate acute, well localized “first” or fast pain, and 2) C-fibers, which are 
small diameter unmyelinated afferents that convey poorly localized, “second” or 
slow pain [9]. Another group of afferent fibers are A-beta (Aβ)-fibers. These fibers 
are large diameter myelinated and rapidly conducting that respond to innocuous 
stimulation (i.e. light touch). Nociceptors are unipolar neurons whose cells bodies 
are located in the dorsal root ganglia (DRG [for the body]) and trigeminal 
ganglion (for the face). These neurons give rise to a single axon that innervates 
peripheral target tissue and central axonal branch that enters the CNS to 
synapse on nociceptive second order neurons (interneurons) [9, 10]. Primary 
afferent nerve fibers project to the dorsal horn, which receives input from the 
periphery. Within the dorsal horn, the Aδ-fibers project to laminae I and V, C-
fibers project to laminae I and II, and Aβ-fibers project deep within laminae III, IV, 
and V (Figure 1.1). Spinal cord neurons within lamina I generally respond to 
noxious stimuli, laminae III and IV non-noxious stimuli, and lamina V noxious and 
non-noxious stimuli [9]. Lamina II is comprised mostly of interneurons (both 






Figure 1.1 Connections between primary afferent fibers and the spinal cord. 
The unmyelinated, peptidergic C (red) and myelinated Aδ nociceptors (purple) 
terminate most superficially, synapsing upon large projection neurons (red) 
located in lamina I and interneurons (green) located in outer lamina II. The 
unmyelinated, non-peptidergic nociceptors (blue) target interneurons (blue) in the 
inner part of lamina II. By contrast, innocuous input carried by myelinated Aβ 
fibers (orange) terminates on interneurons in the ventral half of the inner lamina 
III/IV, whereas a second set of projection neurons within lamina V (purple) 










Nociceptors are excited only when stimulus intensities reach the noxious 
range [9]. After excitation, the peripheral terminal of the nociceptor transduces 
the external stimuli and initiates an action potential, which is conducted by the 
axon. The cell body in the DRG controls the identity and integrity of the neuron, 
which then relays this information to the central terminal (located in the dorsal 
horn), where it is transferred through the release of a variety of 
neurotransmitters, such as glutamate or substance P, to second order neurons at 
central synapses [10]. Axons of the second order neurons in the dorsal horn 
transfer this information across the anterior white commissure (midline of spinal 
cord) to the contralateral side of the spinal cord, where it ascends in the 
anterolateral white matter to the brainstem and thalamus. Within the thalamus, 
nociceptive information is encoded regarding to the type, intensity, and location 
of the pain. Next, the second order neurons synapse with third order neurons, 
within the thalamus, which then transmit the information to the somatosensory 
cortex where it is integrated and undergoes cognitive and emotional 
interpretation of the painful stimulus [2]. This sensory pathway is known as the 
spinothalamic pathway (Figure 1.2). The projection neurons that form this 
pathway originate predominantly in laminae I, II, and V of the spinal dorsal horn. 
This pathway relays information about pain and temperature. 
 
The job of the nociceptive system is to enable and enforce protective 
behavioral responses such as withdrawal or avoidance of any painful stimuli. In 
case of an injury, the affected tissue becomes more vulnerable, therefore the  
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Figure 1.2 Anatomy of the pain pathway. Primary afferent nociceptors convey 
noxious information to projection neurons within the dorsal horn of the spinal 
cord. A subset of these projection neurons transmits information to the 
somatosensory cortex via the thalamus, providing information about the location 
and intensity of the painful stimulus. Other projection neurons engage the 
cingulate and insular cortices via connections in the brainstem (parabrachial 
nucleus) and amygdala, contributing to the affective component of the pain 
experience. This ascending information also accesses neurons of the rostral 
ventral medulla and midbrain periaqueductal gray to engage descending 
feedback systems that regulate the output from the spinal cord [9]. Taken from 









nociceptive system adapts by locally lowering nociceptive thresholds and 
facilitating nociceptive responses. This adaptation enhances the vulnerability of 
the tissue, thereby ensuring adequate tissue protection. These behavior 
adaptations result in the development of allodynia (painful response to non-
noxious stimuli) and hyperalgesia (exaggerate painful response to noxious 
stimuli). Allodynia and hyperalgesia are an appropriate shift in pain threshold to 
prevent further tissue damage. However, allodynia and hyperalgesia may persist 
long after the initial cause of injury, possibly due to dysfunction of parts of the 
PNS and CNS. Therefore, allodynia and/or hyperalgesia, becomes maladaptive 
rather than protective, and the pain is no longer a meaningful homeostatic factor 
or symptom of a disease but rather a disease on its own [6]. 
 
Aβ-fibers are thought to contribute to allodynia symptoms seen in pain 
patients. This is facilitated through several mechanisms: 1) Aβ-fibers sprout to 
deeper areas of laminae II, which is the area that C-fibers normally occupy; and 
2) Aβ-fibers undergo a switch in their phenotype (due to inflammation) and begin 
synthesizing substance P [6, 11]. Nerve injury causes degeneration of central 
terminals of C-fibers in lamina II, thus depriving pain transmission neurons in the 
dorsal horn of nociceptive input. The degeneration of C-fibers triggers surviving 
Aβ-fibers in laminae III and IV to sprout into areas in lamina II, which are normally 
occupied by C-fibers and potentially establish contacts with deafferentated pain 
transmission neurons. Further compounding the situation, Aβ-fibers undergo a 
phenotypic transformation to a substance P-synthesizing mode, thereby 
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enhancing the responsiveness of spinal nociceptive neurons [6, 12] (Figure 1.3). 
Therefore, the reorganization and phenotypic changes associated with nerve 
injury allows non-noxious stimuli to reach lamina II (a pain transmission region of 
the spinal cord), resulting in light touch becoming transmissible as pain also 
known as mechanical allodynia [11]. 
 
Hyperalgesia can be classified as primary or secondary hyperalgesia. 
Primary hyperalgesia occurs at the site of the injury, and is mainly due to the 
sensitization of nociceptive nerve endings. This is typically reflected by an 
increase response to heat stimuli [13]. Secondary hyperalgesia occurs in the 
uninjured tissue surrounding the site of the injury. This form of hyperalgesia is not 
caused by the sensitization of the nociceptive nerve endings, but due to changes 
in the processing of sensory information in the CNS [6]. This form of hyperalgesia 
is characterized by an increased response to mechanical stimuli, rather than 
thermal [13]. Therefore, hyperalgesia can arise from both peripheral and/or 
central mechanisms (also known as peripheral and central sensitization). 
 
Peripheral sensitization is produced when nociceptor terminals become 
exposed to products of tissue damage and/or inflammation [14]. Peripheral nerve 
injury provokes recruitment and activation of immune cells at the site of the nerve 
injury. Immediately after nerve injury, a release of inflammatory mediators by 
activated nociceptors or non-neural cells (mast cells, basophils, platelets, 
macrophages, neutrophils, endothelial cells, keratinocytes, and fibroblasts) that 
11 
 
Figure 1.3 Nerve injury-induced structural and neurochemical reorganization. 
Under normal conditions (top), myelinated Aβ-fibers terminate in lamina III/IV, 
whereas C-fibers terminate in lamina I/II. Substance P is expressed only in 
unmyelinated or thinly myelinated afferent fibers. After nerve injury (bottom), Aβ-
fibers sprout into the lamina II region vacated by central terminals of C-fibers; 
large DRG neurons express substance P. Consequently, non-noxious stimuli can 
activate pain transmission pathways, resulting in mechanical allodynia in patients 








reside within or infiltrate into the injured area. Collectively, these factors release 
signaling molecules what are known as the “inflammatory soup” [9, 10, 15], such 
as neurotransmitters, neuropeptides (calcitonin gene-related peptide [CGRP], 
substance P, bradykinin), eicosinoids and related lipids (prostaglandins, 
thromboxans, leukotrienes, endocannabinoids), cytokines, chemokines, and 
extracellular proteases. Nociceptors express one or more cell-surface receptors 
capable of recognizing and responding to each of these proinflammatory or 
proalgesic agents, thus enhancing the excitability of the nerve fiber and 
heightening its sensitivity to temperature and touch [9]. Along with inflammatory 
responses, the Schwann cells release chemical signals that promote axonal 
growth (nerve growth factor [NGF]), which is retrogradely transported to the cell 
bodies of primary sensory neurons [16]. In the nucleus of the nociceptor, NGF 
promotes the increase of pronociceptive proteins (substance P, TRPV1, and the 
Nav1.8 voltage-gated sodium channel subunit) [17, 18]. Together, these changes 
enhance the excitability of the nociceptor and amplify the neurogenic 
inflammatory response. 
 
Central sensitization is defined as “an increased responsiveness of 
nociceptive neurons in the CNS to their normal or subthreshold afferent input” [6]. 
When neurons in the dorsal horn of the spinal cord are subject to central 
sensitization, they may develop an increase in spontaneous activity, a reduction 
in the threshold for activation by peripheral stimuli, or an enlargement of their 
receptive fields [19]. The mechanisms for central sensitization include an 
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alteration in glutamatergic neurotransmission/ N-methyl-D-Aspartate (NMDA) 
receptor-mediated hypersensitivity and loss of tonic inhibitory control (discussed 
in Modulation of pain section) [9]. Glutamate is the main neurotransmitter in 
nociceptors. It binds to several receptors on postsynaptic neurons in the dorsal 
horn of the spinal cord, including ionotropic amino-3-hydroxy-5-methyl-4-
isoxazole propionate (AMPA), NMDA, and glutamate receptor subtypes (mGlur). 
The NMDA receptor is one of the main triggers and effectors of central 
sensitization. Under resting conditions the NMDA receptor channel is blocked in 
a voltage-dependent manner by a magnesium (Mg2+) ion sitting in the receptor 
pore. However, sustained release of glutamate and neuropeptides (substance P 
and CGRP) leads to sufficient membrane depolarization that forces Mg2+ to leave 
the NMDA receptor pore. Removal of Mg2+ allows entry of calcium into the 
neuron, which activates numerous intracellular pathways (phospholipase 
C/protein kinase C [PLC/PKC], phosphatidylinositoal-3-kinase [PI3K], and 
mitogen-activated protein kinase [MAPK] pathways) that contribute to central 
sensitization [19]. As injured tissue heals, the sensitizations induced by 
peripheral and central mechanisms are relatively short lasting and reversible. 
However, sensitization becomes pathological when the afferent fibers or central 
pathways become damaged, which can occur in pathological conditions such as 
diabetes, shingles, multiple sclerosis, etc., ultimately leading to neuropathic pain. 
 
Many Aδ- and C-fibers display somatic sodium channels. These sodium 
channels include the sensory nerve specific (SNS, also known as PN3) and 
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sensory nerve specific 2 (SNS2, also known as NaN) sodium channels, which 
are tetrodotoxin (TTX)-resistant sodium currents, and alpha-III sodium channels 
(TTX-sensitive sodium currents). Voltage-gated sodium channels generate and 
propagate action potentials in excitable cells. Nerve injury can result in an 
abnormal expression of peripheral sodium channels (Figure 1.4). Nerve injury 
produces a painful state due to an increase in excitation of sodium channels. 
After nerve injury there is a down regulation of the SNS and NaN sodium channel 
genes in the soma, and SNS is translocated to the site of the injury. After the 
down-regulation of SNS and NaN sodium channels, the expression of alpha-III 
sodium channel gene is upregulated in the DRG. These changes in sodium 
channel gene expression produces electrophysiological changes in the DRG 
neurons causing them to fire spontaneously or at inappropriate high frequencies 
[12, 20]. 
 
1.1.3 Modulation of pain 
Spinal nociceptor neurons are under constant and powerful inhibitory 
control that processes sensory information in the dorsal horn for normal pain 
perception. The inhibitory system serves to maintain proper nociception by 
attenuating the responses of nociceptive neurons by maintaining proper 
response levels during nociception. This is obtained by, muting nociceptive 
neurons in the absence of noxious stimuli, preventing crosstalk between sensory 




Figure 1.4 Sodium channel-mediated ectopic activities. Under normal conditions 
(top), the SNS (hourglass shapes) and NaN (circles) are expressed on the cell 
membrane of DRG neurons. After nerve transaction (middle), the alpha-III 
sodium channel (squares) is expressed and SNS is translocated from the DRG 
soma to the site of injury and neuroma formation (marked by an X). As result 
(bottom), alpha-III accumulates at the DRG, and SNS accumulates at the 
neuroma (dashed circles), leading to ectopic activity at both sites (flare, denoted 








lastly, limiting the spread of excitatory stimuli to somatotopic areas of the central 
nervous system [6]. 
 
The brain has modulatory circuits whose main function is to regulate the 
perception of pain. As the ascending nociceptive information passes through the 
brainstem and reaches the brain, a network of brainstem structures and 
pathways that exert a modulatory effect on nociceptive transmission is activated 
[2]. The initial site of modulation is in the dorsal horn of the spinal cord. The 
descending modulatory effect is applied by inhibiting the release of 
neurotransmitters from the primary afferent fiber or by inhibiting the function of 
the neurotransmitter receptor on the postsynaptic neuron [2], thus controlling the 
transmission of nociceptive information to the higher regions of the brain. 
Descending control of spinal nociception arises from a number of supraspinal 
sites. Periaquaductal gray (PAG) has been established as a major component of 
the pain modulatory circuitry. PAG surrounds the cerebral aqueduct in the 
midbrain. It is heavily interconnected with the hypothalamus and limbic forebrain 
structures. The PAG projects to the rostral ventromedial-medulla (RVM), which in 
turn sends its output to terminals in laminae I, II, and V of the dorsal horn that are 
important in nociceptive function. The PAG-RVM system plays a pivotal role in 
organizing strategies for coping with intrinsic and extrinsic stressors, and is the 
central site of action of analgesic agents such as opioids, cyclooxygenase 
inhibitors, and cannabinoids [21]. This system acts as a negative feed-back loop 
for the control of the nociceptive input [5]. 
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Nerve injury disrupts this endogenous pain inhibitory system by inducing 
changes in the spinal gamma-aminobutyric acid (GABA)-nergic and glycine 
systems. The major fast inhibitory neurotransmitters in dorsal horn of the spinal 
cord are GABA and glycine. GABA and glycine are coreleased at inhibitory 
synapses laminae I and II of the spinal cord [6]. Upon binding to its receptor, 
GABA activates chloride-permeable ion channels, which hyperpolarize neurons 
and impair the dendritic propagation of excitatory signals [22]. However, 
diminished GABA- and glycine-mediated inhibition in the dorsal horn of the spinal 
cord leads to pathologic pain in various states. For example, in animals with 
peripheral nerve injury (unilateral sciatic nerve ligation) that exhibited thermal 
hyperalgesia, spinal cord levels of GABA transporter protein (GAT-1) were 
reduced by 37% compared to controls [23]. Also, blocking the GABA and glycine 
receptors in the spinal cord can induce mechanical allodynia in uninjured animals 
[24]. Therefore, GABA and glycine play an important role in modulating 
nociceptive input in the dorsal horn of the spinal cord. 
 
1.1.4 Management of pain 
To date, there is no treatment that prevents the development of or 
sufficiently controls symptoms associated with neuropathic pain [3]. It has been 
estimated that 66% of patients with neuropathic pain do not experience sufficient 
pain relief [23]. The overall goal of pain management is to return the individual 
back to a productive life. There are two approaches used in order to obtain this 
goal: 1) pharmacological treatment strategy and 2) non-pharmacological 
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treatment strategy. There is a collection of drugs, for which randomized control 
clinical trials have shown efficacy in managing neuronal hyperexcitability in 
neuropathic pain. These include antidepressants, anticonvulsants, opioids, 
NMDA antagonists, non-steroidal anti-inflammatory drugs (NSAIDs), and topical. 
However, the efficacy of pharmacological treatment for neuropathic pain is still 
insufficient. As consequence, numerous non-pharmacological treatment 
strategies have been developed in order to reduce symptoms associated with 
neuropathic pain. For example, Figure 1.5 describes a survey of 22 non-
pharmacological treatments for pain that was mailed to 732 practitioners, which 
were members of the International Association for the Study of Pain [25]. In this 
survey, practitioners were asked to list in order the non-pharmacological therapy 
treatment that they most frequently or referred their patients to participate in. 
Seventy-two percent of practitioners recommended the use of exercise to their 
patients in order to treat neuropathic pain symptoms. Of these practitioners, 80% 
believed that exercise should be part of legitimate medical practice. Surveys 
have shown that patients who participate in exercise to treat their neuropathic 
pain symptoms, rate exercise to be an effective non-pharmacological treatment. 
[26]. However, according to the survey conducted by Berman and Bausell 
(2000), only 59% of practitioners reported having sufficient knowledge to discuss 
the use of exercise as a therapy treatment with their patients. Therefore, 
knowledge of the effectiveness of exercise for treating neuropathic pain related 
symptoms is clearly warranted. 
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Figure 1.5 Non-pharmacological therapies. Proportion of respondents who A.) 
used non-pharmacological therapies in their practice or referred their patients to 
other providers, B.) reported sufficient knowledge to discuss therapies with 
patients, and C.) considered therapies a part of legitimate medical practice 




Figure 1.5 Non-pharmacological therapies.   
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Neuropathic pain, often responds poorly to pharmacological interventions. 
As a non-pharmacological approach, several studies have investigated the 
effects aerobic exercise on symptoms associated with chronic or neuropathic 
pain. Exercise was shown to have beneficial actions on patients that suffered 
from chronic pain symptoms associated with fibromyalgia [27], chronic neck pain 
[28], chronic low back pain [29] and in animals experiencing peripheral 
neuropathic pain [30], spinal cord injury [31], and chronic muscle pain [32]. These 
studies have shown that acute and chronic aerobic exercise can improve pain 
thresholds with chronic and/or neuropathic pain, and in humans the reduction in 
symptom severity can last as long as 1 year after cessation of the exercise 
training. The analgesia experienced in these studies is believed to be exercise-
induced. 
 
Exercise-induced analgesia is poorly understood; however, there are 
several plausible mechanisms that may exist. Mechanisms involved include the 
opioid and non-opioid systems. As reviewed by Koltyn (2000), the release of 
endogenous opioids is the most commonly tested and proposed mechanism for 
exercise induced analgesia in healthy individuals. The same mechanism was 
reported to produce analgesic effects in chronic muscle pain after acute bouts of 
exercise. As reported by Bement and Sluka, exercise increased mechanical 
thresholds in rats with chronic muscle pain. However, these anti-allodynic effects 
of exercise were reversed with naloxone (an opioid antagonist), suggesting the 
activation of the endogenous opioid system even at this low intensity [33]. 
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Endogenous opioids suppress calcium influx and the excitation and/or 
neurotransmitter release in many neuronal systems [34]. 
 
As for the non-opioid systems, neurotrophins have been examined for its 
potential involvement in analgesic responses that occur following exercise. 
Neurotrophins (brain derived neurotrophic factor [BDNF], NGF, and neurotrophin-
3 [NT-3]) are a family of structurally and functionally related peptides that 
mediate potent survival and differentiation effects on a wide variety of neuronal 
populations in the CNS and PNS [35]. Extensive research has attributed 
neurotrophins playing an important role in modulating pain. Recently, numerous 
studies have shown that aerobic exercise, whether forced (via treadmill) or 
voluntary (via free-access running wheels), can increase neurotrophin expression 
[31, 36-42]. Aerobic exercise (via treadmill) has been shown to attenuate 
allodynia in spinal cord injured animals. This amelioration of allodynia was 
attributed to increases in BDNF in the lumbar region of the spinal cord and 
soleus muscle, which correlated with pain threshold levels. The modulatory effect 
seen in this study may be due to the ability for BDNF to increase β-endorphins in 
the PAG and dorsal spinal cord [43]. BDNF expressing neurons are present in all 
portions of the PAG and RVM-projecting PAG neurons [44]. Studies have shown 
that administration of BDNF into the PAG produces analgesia in rats [44, 45]. 
This is likely due to the downregulation of the tyrosine kinase receptor B (TrkB 
[contributes to pain facilitation]) signaling in the RVM neurons, which produces 
descending inhibition of nociceptive inputs potentially through the activation of 
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analgesic agents such as opioids (β-endorphins), thus inhibiting the transmission 
of pain [44, 46]. 
 
1.2 Diabetic neuropathy 
1.2.1 Epidemiology of diabetic neuropathy 
Neuropathy is a common secondary complication of diabetes. Currently, 
20.8 million people in the United States are affected by diabetes, and by the year 
2010 it is predicted to increase to approximately 220 million people worldwide. 
Recently, a population-based study reported that more than half of patients who 
have type 1 and 2 diabetes develop diabetic neuropathy (DN) [47]. Of these 
patients with DN, 15% to 30% suffer from painful diabetic neuropathy, whereas 
the remainder experiences a negative phenomenon, such as numbness [48]. 
Clinical symptoms associated with DN involve poor gait and balance associated 
with large sensory fibers, and abnormal cold and/or heat sensation associated 
with small sensory fibers. Chronic pain associated with diabetes is represented 
by hyperalgesia, allodynia, parethesias and spontaneous pain [49, 50]. 
Symptoms are described as prickling, tingling, “pins and needles”, burning, 
crawling, itching, abnormal sensation to temperature, and pain. Over time these 
symptoms may advance from the toes up the foot and leg and may involve the 
fingers and hands [51]. DN is associated with structural changes in the peripheral 
nerve that includes axonal atrophy, demyelination, loss of nerve fibers, and the 
blunted regeneration of the nerve fibers [52-54]. Nerve fibers maintenance in the 
periphery is balanced between nerve degeneration and regeneration under non-
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neuropathic conditions, however if nerve degeneration exceeds nerve 
regeneration then fiber loss may progress. Therefore, the progressive nerve fiber 
loss in DN may be due to an impaired ability of the diabetic nerve to regenerate 
in response to the degenerative process [53]. 
 
1.2.2 Pathogenesis of diabetic neuropathy 
In diabetic patients, the development and progression (distal to proximal 
direction and is axon length-dependent) of DN is thought to be mainly due to 
increased blood glucose concentrations (hyperglycemia). A persistent elevation 
in blood glucose leads to glucose toxicity [55]. Glucose toxicity contributes to β-
cell dysfunction and the pathology of other complications (e.g. DN) associated 
with diabetes [55]. The pathogenesis of DN includes increased polyol pathway 
activation, advanced glycation end products (AGE), activation of PKC, poly(ADP-
ribose) polymerase pathway (PARP), vascular insufficiency, and a reduction in 
neurotrophic factors (i.e. GDNF) [49, 50, 53]. These mechanisms lead to 
increases in oxidative stress and nerve dysfunction, which results in disturbances 
in the nerve degeneration/regeneration process. 
 
In diabetes, hyperglycemia causes a 4-fold increase in neuronal glucose 
levels. If an elevation in blood glucose continues, then intercellular glucose 
metabolism leads to neuronal damage known as glucose neurotoxicity [56]. 
Axons are vulnerable to hyperglycemic damage due to their direct access to 
nerve blood supply [49]. Due to metabolic changes that occur in diabetes, C-
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fibers have been proposed to be the most susceptible to damage because they 
are not protected with a myelin sheath. Damage to the C-fibers can lead to 
neuropathic pain due to mechanisms that were described earlier, such as 
sprouting and phenotypic changes of Aβ-fibers, alterations in sodium channels in 
the DRG, and increases in glutamate activity. 
 
1.2.3 Management of diabetic neuropathy 
Therapies for DN are divided into treatments that target the underlying 
pathogenic mechanisms and those aiming to relieve symptoms [49]. Pathogenic 
mechanism includes strict glycemic control through continuous glucose 
monitoring, whereas positive and negative symptoms associated with DN are 
treated with one or more medications [57]. Pharmacological therapies include 
treating the symptom itself or the cause of the DN in an attempt to reverse DN by 
diminishing the biochemical aberrations which induce neuronal damage [49]. 
However, the only proven method currently available to prevent DN and/or slow 
the progression of this disease is strict glycemic control [58]. Therefore, other 
therapy treatments need to be explored, such as exercise which has shown to be 
able to improve glycemic control [59]. 
 
Exercise has long been recognized as a part of therapy in the 
management of diabetes, yet many persons with diabetes fail to participate in 
basic physical activity due to secondary diabetic complications (i.e. DN). Recent 
studies have shown that exercise has beneficial effects on painful symptoms in 
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the setting of diabetes. In Type 1 and 2 diabetic patients who did not display any 
signs or symptoms of DN, aerobic exercise (brisk walking on a treadmill) reduced 
the onset of both motor (0% versus 17%) and sensory (7% versus 30%) 
neuropathy compared to sedentary diabetic patients [60]. As for patients with 
impaired glucose tolerance, lifestyle intervention (consisted of diet and exercise 
counseling) can also improve pain symptoms [61]. These improvements in pain 
thresholds may be due to the ability of exercise to increase myelin sheath 
thickness, which were seen in exercised diabetic animals that exhibited 
improvements in axonal and motor function [62]. These studies have shown that 
exercise can prevent the development DN and increase pain thresholds in 
patients with impaired glucose tolerance; however, the efficacy of exercise 
exerting a similar effect in diabetic patients with signs and symptoms with DN has 
yet to be explored. 
 
1.3 Glial cell line-derived neurotrophic factor (GDNF) 
GDNF is a neurotrophic factor that belongs to the transforming growth 
factor-β superfamily. GDNF specifically binds to GDNF family receptor α (GFRα), 
which then forms a complex with a receptor tyrosine kinase RET. RET can 
activate several intracellular signaling cascades (MAPK, PI3K, and 
phospholipase C  [PLC- ]) (Figure 1.6), which regulate cell survival, 
differentiation, proliferation, migration, chemotaxis, branching morphogenesis, 
neurite outgrowth, and synaptic plasticity [63, 64]. GDNF has a trophic effect in 
the CNS, peripheral sensory, sympathetic, and spinal motor neurons [65]. 
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Varieties of tissues synthesize and secrete GDNF [63]. GDNF expression has 
been shown in various regions of the CNS [66, 67], PNS [66], and peripheral 
tissues [68, 69]. GDNF has been identified in the striatum, hippocampus, cortex, 
cerebellum, and spinal cord, Schwann cells, and DRG. It is believed that the 
Schwann cells are the major source of GDNF in the PNS [70], however it has 
also been shown to be produced by the glial satellite cells in the DRG neuron 
[71]. GDNF expression has also been identified in many peripheral non-neuronal 
tissues, such as the lung, liver, and ovary of adult rats [68] and the skeletal 
muscle of humans [69]. These findings provide evidence that GDNF is detectable 
in a number of nervous system structures and other non-neuronal tissues. 
 
1.3.1 GDNF and pain 
GDNF has been hypothesized to play an important role in the modulation 
of nociceptive signals especially during neuropathic pain states. However, the 
expression of GDNF in models of neuropathic pain has yielded contradictory 
results. Recent studies have shown that nerve injury (via chronic constrictive 
injury and spinal nerve ligation models) diminishes GDNF and RET expression 
in the sciatic nerve and DRG [72, 73]. Nagano et al. (2003) reported that in 
animals experiencing neuropathic pain, within 2 weeks GDNF and RET 
expression can be reduced by 40% in the DRG. On the contrary, studies have 
shown that transection of the sciatic nerve can result in increases in GDNF and 
its receptor GFRα-1 in the sciatic nerve and DRG. [74, 75]. After nerve injury, 
GDNF has been reported to increase 20-fold in the sciatic nerve [75] and these  
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Figure 1.6 GDNF-family ligands and receptor interactions. GDNF binds GFRα, 
which then forms a complex with RET; therefore, activating several intracellular 









changes in expression can be affected for as long as 5 months [74]. Reasons as 
to contradictory results in GDNF expression after nerve injury remains unknown, 
however it may be due to the type of nerve injury model (chronic constrictive 
injury and spinal nerve ligation versus nerve axotomy) [73] or it may be 
associated with differences in activities of primary afferents between models 
[72]. However, these results suggests that GDNF is an important factor in the 
events following peripheral nerve injury, and the possible dysfunction of GDNF 
signaling in the nociceptive afferent system may contribute to the development 
and/or maintenance of neuropathic pain states. 
 
GDNF has been shown to have potent analgesic effects in the state of 
neuropathic pain. Studies have reported that the administration of GDNF can 
ameliorate behavioral sensitivity associated with neuropathic pain [72, 76-79]. 
Possible mechanisms for attenuating behavioral sensitivity associated with 
neuropathic pain include promoting the survival of non-peptidergic nociceptive 
C-fiber neurons (isolectin B4 [IB4] binding), thereby decreasing Aβ-fiber 
sprouting [80], regulating sodium channels [77], and by regulating neuropeptides 
[76]. 
 
C-fiber nociceptors can be divided into two groups; 1) peptidergic 
(depends on NGF for survival), and 2) non-peptidergic (depends on GDNF for 
survival) [81]. Non-peptidergic C-fibers comprise of about 40% of the cells in the 
DRG. Nerve injury has been shown to reduce C-fibers by 50% [80]. This 
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reduction in C-fibers induces sprouting of myelinated sensory afferents (Aβ-
fibers) into laminae I and II. However, administration of GDNF has been shown 
to rescue the reduction of C-fiber neurons in the DRG, thus preventing the 
sprouting of Aβ-fibers [80]. 
 
SNS and NAN sodium channels are expressed in 52% and 72% of IB4 
binding C-fibers, respectively [82]. As described earlier, spontaneous activity of 
the nociceptor is due to the down-regulation of SNS and NaN sodium channels 
and up-regulation of alpha-III sodium channels [20]. In vitro and in vivo studies 
have demonstrated that administration of GDNF restores SNS and NaN sodium 
channel levels [77, 82] and suppress alpha-III sodium channel levels in the DRG 
[77]. This restoration of sodium channel function reduces ectopic discharges; 
therefore mechanical and thermal thresholds are reverted to normal levels in 
nerve injured animals [77]. 
 
A subpopulation of IB4 binding C-fiber neurons expresses the 
neuropeptide somatostatin. Somatostatin can inhibit the pronociceptive 
peptides, substance P and CGRP, from primary afferents [83]. Using the spared 
nerve injury (SNI) model, Adler et al. 2009, reduced mechanical allodynia by 
locally applying GDNF to the injured site of the sciatic nerve. They associated 
these reductions in allodynia to increases in prosomatostatin levels in the DRG. 
In vitro, they confirmed this assumption by showing that by exposing DRG 
neurons directly to GDNF, somatostatin increased nearly 3-fold, which lead to an 
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increased secretion of potassium. Potassium plays a key role in establishing the 
resting membrane potential and in the repolarization phase of action potentials 
in neurons. To date, GDNF is the only neurotrophic factor that has been found to 
stimulate somatostatin expression [76]. Together, these results suggest that 
GDNF may be a viable treatment for attenuating behavioral sensitivity 
associated with neuropathic pain. 
 
1.3.2 GDNF and diabetic neuropathy 
DN is associated with impaired neurotrophic support. Many studies have 
examined how diabetes alters neurotrophins (NGF, BDNF, NT-3, etc.) in the 
setting of DN; however, little is known about how diabetes affects GDNF 
production and its contribution to DN. Recent studies have reported that diabetes 
alters GDNF expression in central and peripheral tissues [84-87]. GDNF has 
been implicated to play an important role in the pathogenesis of DN. It is well 
know that diabetes induces alterations in electrophysiological functions that 
results in reductions in nerve conduction velocity. In diabetic rats with 
neuropathic symptoms (decreased nerve conduction velocity), GDNF is 
decreased. However, following GDNF gene delivery, these neuropathic 
symptoms associated with diabetes were alleviated [54]. This may be due to the 
restorative effects GDNF has on degenerating nerves. Earlier, it has been shown 
that administration of GDNF stimulated axon growth and branching in diabetic 
mice, thus improving innervations deficits caused by diabetes [84]. These results 
suggest that diabetes may alter GDNF expression and reductions in GDNF may 
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be associated with neuropathic pain, thus GDNF may play a role in attenuating 
behavioral sensitivity linked to DN. 
 
1.3.3 GDNF and exercise 
Numerous studies have reported that acute and chronic bouts of exercise 
increase neurotrophins (BDNF, NGF, and NT-3) in both injured and non-injured 
animals [31, 36-39, 41, 42]. These neurotrophins have reportedly been increased 
in various neuronal (spinal cord and brain) and non-neuronal (skeletal muscle) 
tissues. Few studies have assessed the effects exercise has on GDNF 
expression; however, studies have shown that acute and chronic exercise can 
alter GDNF expression in various neuronal and non-neuronal tissues [40, 88-90]. 
GDNF has been assessed in injured and non-injured animals and also Parkinson 
diseased animals following exercise. In non-injured rats, GDNF protein levels 
were assessed in the cervical region of the spinal cord [89] and in skeletal 
muscle (soleus, gastrocnemius, and pectoralis major) [90]. Forced exercise (via 
treadmill) increased GDNF protein levels in skeletal muscle, whereas, GDNF 
levels in the cervical region of the spinal cord remained unchanged.  However, 
non-injured animals who were subjected to hindlimb unloading (suspension from 
hindlimb) exhibited significant decreases in GDNF levels of the soleus and 
gastrocnemius, suggesting that activity levels may modulate GDNF protein levels 
in skeletal muscle. In animals with spinal cord injury (transection of thoracic 
[T10]) and Parkinson disease (a neurodegenerative disease in the CNS), forced 
exercise (via motorized cycle apparatus and treadmill, respectively) increased 
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GDNF gene expression and protein levels, respectively, in the soleus muscle and 
striatum, respectively. In both animal models, exercised animals showed a better 
functional and behavioral recovery, which were attributed to increases in GDNF 
[40, 88]. Suggesting that increases of GDNF with exercise may exert a 
neuroprotective effect in the CNS. All the above reports demonstrated that forced 
exercise increases GDNF both centrally and peripherally, and these increases in 
GDNF may have beneficial effects on motor control; however further research is 
needed to determine whether the same can be seen in sensory mechanisms. 
 
1.4 Axonal transport 
Axonal transport is a neuronal mechanism by which various molecules are 
transported to maintain normal metabolism, physiological activity, and structural 
integrity [91]. The transfer of information between neurons is bi-directional 
(anterograde and retrograde transport). Anterograde transport maintains the 
structural and functional integrity of the axon, whereas retrograde transport 
serves as a feedback system to the cell body about the status quo pertaining to 
the peripheral parts of the axon [92]. Proteins can be internalized at the axon 
terminals (and be involved in retrograde transport) or at the somatodendritic 
membranes (and be involved in anterograde transport). After internalization, 
proteins are sorted into one of several subcellular pathways: 1) they may be 
recycled to the surface membrane, either as a ligand-receptor complex, or as a 
receptor only after dissociation of ligand and receptor; 2) upon internalization of 
trophic factors at the axon terminal, the ligand-receptor complex can be sorted 
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into a transport vehicle, vesicle, or endosome, for retrograde transport; 3) upon 
arrival at the cell body or after internalization at somatodendritic domains, 
proteins can be sorted to the Golgi system for anterograde transport; 4) upon 
internalization at the axon terminal and retrograde axonal delivery to the cell 
body, proteins may be directed to dendrites at the dendritic membranes to be 
packaged for release at synapses; and 5) instead of routing into recycling 
pathways, proteins may be targeted for degradation via endosome/lysosome or 
via proteasome pathways. Once the internalized the protein is then transported 
to the axon terminals (via anterograde transport) or to the somatodendritic 
domains (via retrograde transport) [93]. 
 
Retrograde transport for neurotrophic factors is achieved through 
endosomal trafficking. This comprises of the neurotrophic factor being taken up 
by receptor mediated endocytosis into clathrin-coated vesicles. These vesicles 
fuse with early endosomes in the axon terminal, which then travels retrogradely 
along axonal microtubules using dynein motor proteins. Upon reaching the cell 
body, the transport vesicles fuse with late endosomes and finally to lysosomes 
[94]. After internalization, proteins that are destined for anterograde axonal 
transport pass through the Golgi apparatus where they are then packaged into 
large dense core vesicles. Once the vesicle that contains the neurotrophic factor 
is properly packaged and loaded onto the anterograde machinery, kinesin motor 
proteins transport the neurotrophic factor to the axon terminus. After antero- and 
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retrograde axonal transport the protein can then be released from the neuron 
[93]. 
 
1.4.1 GDNF/ neurotrophin axonal transport and diabetes 
Studies have reported that GDNF can be transported anterogradely [95, 
96] and retrogradely [97] within neurons. Anterograde transport of GDNF has 
been reported in the sciatic nerve [95] and the hypoglossal nerve [96] and 
retrograde transport has been shown to occur in the motor neurons [97]. Studies 
have revealed that GDNF production is decreased in peripheral tissues of 
diabetic mice [54, 84]. Therefore, the availability of GDNF through axonal 
transport is important for the survival of motor and sensory neurons. GDNF 
axonal transport in diabetic animals has yet to be explored. However, several 
studies have shown that diabetes reduces axonal transport of neurotrophins 
(BDNF, NGF, and NT-3) in the sciatic [98-100] and cervical vagus [101] nerves. 
Reports have shown that diabetes reduces endogenous neurotrophin transport 
both anterogradely and retrogradely [98, 100] and this reduction can be up to 
50% [99]. However the mechanisms of diabetes-induced diminished neurotrophin 
support are not known. Possible mechanisms for diabetes-induced reduction in 
the transport of neurotrophins include: 1) alterations in access to transportable 
neurotrophins (alteration in synthesis, storage, or processing); 2) alterations in 
receptors involved in recognition and transport (changes in synthesis, ligand 
binding, phosphorylation, internalization, etc.); and 3) general changes in the 
ability of the neuron to maintain machinery in transport [101]. 
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1.4.2 Axonal transport and exercise 
Earlier studies examined whether increases in neuronal activity would 
result in an increase in axonal transport by investigating the effects of acute [102] 
and chronic [91, 103, 104] exercise training (via treadmill [range 2 to 13 weeks]). 
In the sciatic nerve, acute and chronic exercise can increase protein transport up 
to 20% and 50%, respectively [102, 104], and this increase can occur in both 
intact and deafferented nerves [91]. These increases are due to the fact that 
exercise increases the transport velocity of proteins within the sciatic nerve. The 
reasoning behind this increase in protein transport and velocity may be due to 
that trained neurons are more responsive to alterations to their immediate 
neuronal environment. For example, exercise increases neuronal activity leading 
to changes at the nerve terminal. Consequently, the axonal transport of proteins 
are increased in order to compensate for the effects exercise has on the distal 
parts of the motoneurons, thus allowing repair and return to normal nerve 
function [91]. The results from these studies show that exercise (training by 
running) does affect axonal transport by increasing protein transport velocities, 
as well as the amount of protein transported. 
 
1.5 Animal models of pain 
1.5.1 Neuropathic pain (peripheral nerve injury) 
The understanding of clinical pain has been greatly accelerated due to the 
development of animal models that reproduces many elements of clinical pain 
syndromes. These models have led to a better understanding of the 
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pathophysiologic neural changes associated with neuropathic pain. Animal 
models of neuropathic pain that increase tactile and thermal sensitivity include: 1) 
spinal nerve ligation (SNL) [105], 2.) chronic constriction injury (CCI) [106], 3.) 
partial sciatic nerve ligation (PSNL) [107], and 4.) spared nerve injury (SNI) [108] 
(Figure 1.7). The most important criteria’s for any animal model of neuropathic 
pain are the ease of the procedure and the ability to reproduce sensory deficits 
such as allodynia, hyperalgesia, and spontaneous pain over a sustained period 
[4]. However, the spinal nerve ligation, chronic constriction injury, and partial 
sciatic nerve ligation models produce several limitations such as the inability to 
separate injured from intact nerve fiber due to the fact that they co-exist in the 
same nerve trunk (CCI and PSNL), nerve regeneration may occur over the 
ligation site (SNL and PSNL), and the number of injured fibers are difficult to 
control, therefore producing injury may become difficult (CCI and PSNL) [109]. 
On the other hand, the SNI model is easy to perform and has been shown to 
produce profound and reliable pain behaviors that closely mimic many features of 
clinical neuropathic pain [108], therefore minimizing potential limitations 
described above [109]. The SNI model involves ligating and sectioning the tibial 
and common peroneal nerves, while sparing the sural nerve, which produces a 
long-lasting mechanical and thermal hypersensitivity. This model also allows the 
investigation of changes in both injured primary sensory neurons and 
neighboring intact sensory neurons and their contribution to the pathophysiology 
of neuropathic pain [110]. 
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Figure 1.7 Animal models of neuropathic pain. 1.) spinal nerve ligation; 2.) 
chronic constriction injury; 3.) partial sciatic nerve ligation; and 4.) spared nerve 








1.5.2 Diabetic neuropathy 
The most common animal model of human diabetes is streptozotocin 
(STZ)-induced diabetes in rodents [111]. STZ is a glucose analogue that 
specifically damages pancreatic β cells [112]. Administration of STZ can rapidly 
produce characteristic signs of type 1 diabetes, such as an increase in food and 
water intake, failure to gain weight, and increased blood glucose levels. These 
animals can survive for periods of weeks to months depending on the severity of 
pancreatic damage induced, while insulin administration can keep animals alive 
for a year or more [113]. Studies have also shown that in rodents, STZ-induced 
diabetes can mimic clinical secondary complications such as painful DN [114, 
115]. STZ-diabetic rats have been shown to develop sustained tactile allodynia, 
which can be measured via von Frey monofilament (technique similarly used in 
clinical practice) [116]. In diabetic patients the progression of painful diabetic 
neuropathy can take years, whereas in rodent it takes weeks. Thus, allowing 
investigators to assess diabetic complications in a more efficient time frame. 
 
1.6 Proposed work 
Currently, there is no treatment to prevent the development or adequately 
control neuropathic pain. As a result, there is an unmet clinical need and an 
ongoing challenge to develop more effective therapies. This can only  be 
achieved if the relationship between the aetiology, mechanisms, and symptoms 
of neuropathic pain are understood [3]. Recent studies have demonstrated that 
aerobic exercise can reduce pain sensitivity in both human and animals 
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experiencing chronic and neuropathic pain. Recently, we have shown in an 
animal model forced aerobic exercise (via swimming) reduces symptoms 
associated with neuropathic pain [30]; however, the exercise-induced 
mechanisms were not researched in this study. In order to better translate these 
findings to humans, it needs to be determined whether voluntary exercise can 
produce similar effects on clinical problems, such as mechanical allodynia and 
hyperalgesia. Balducci et al. (2006) reported that exercise can adequately 
prevent the onset of painful DN in diabetic patients without signs or symptoms of 
DN. However, the ability of voluntary exercise to exert similar effects on diabetic 
patients with signs or symptoms of DN has yet to be explored. Therefore, to 
address this gap in knowledge we have designed a set of experiments that has 
allowed us to assess the effects of voluntary exercise on animal models of 
peripheral neuropathic pain (SNI model) and painful DN (STZ model), as well as 















Effect of voluntary exercise on reducing mechanical sensitivity in nerve 




Persistent pain, mainly neuropathic pain, can be a debilitating disease that 
often responds poorly from pharmacological interventions. The ability of exercise 
to reduce behavioral sensitivity associated with peripheral nerve injury in rodents 
has been reported; however, the exercise-induced mechanisms were not 
explored. The purpose of this study is to determine how peripheral nerve injury 
affects GDNF protein levels and whether voluntary exercise has any influence in 
order to attenuate or delay the behavioral sensitivity associated with neuropathic 
pain. Twenty-five female Sprague Dawley rats (200-250g) were used in this 
study. Sixteen rats were randomized into either the sedentary (Sed-Sham^25 
[n=4]) or exercised (Ex-Sham^25 [n=4]) sham surgery group or sedentary (Sed-
SNI^25 [n=4]) or exercised (Ex-SNI^25 [n=4]) spared nerve injury (SNI) surgery 
group, which participated in the 25 day duration study. The remaining 9 rats were 
randomized to either the sedentary (Sed-SNI^110 [n=4]) or exercised (Ex-
SNI^110 [n=5]) SNI group, which participated in the 110 day duration study. Rats 
in the SNI groups had surgically-induced peripheral nerve injury surgery. 
Following recovery from surgery, rats in the exercised groups were housed in 
standard cages with voluntary running wheels while the sedentary group was 
housed without wheels. Mechanical allodynia and hyperalgesia were assessed 
via von Frey filaments and pin-prick test, respectively. GDNF protein levels were 
examined in the lumbar region of the spinal cord using immunoblot analysis. SNI 
surgery produced behavioral hypersensitivity in both sedentary and exercised 
groups. In both the 25 and 110 day study, voluntary exercise significantly 
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reduced mechanical allodynia and hyperalgesia after SNI. Twenty-five days post 
SNI surgery did not alter GDNF protein levels in the spinal cord; however, over 
time (110 days) GDNF levels significantly increased in the spinal cord of the SNI 
groups. The Sed-SNI^110 and Ex-SNI^110 groups exhibited a 2.3- and 1.6-fold 
increase in GDNF protein levels compared to the Sed-SNI^25 and Ex-SNI^25 
groups, respectively. Voluntary exercise did not change GDNF protein levels in 
either exercised group. Voluntary exercise caused favorable changes in 
behavioral sensitivity following nerve-injury in female rats. This investigation 
supports the use of voluntary exercise to complement current treatment 




Neuropathic pain is initiated or caused by a primary lesion or dysfunction 
in the structure and function to the nervous system [1, 12, 117, 118]. It is 
characterized by sensory abnormalities such as a painful response to a stimulus 
that does not normally provoke pain (allodynia) or an increased response to a 
painful stimulus (hyperalgesia) [4]. Peripheral neuropathic pain is the result of 
damage to the peripheral nervous system (via mechanical trauma, metabolic 
disease, etc.), which involves multiple pathophysiological changes to both the 
PNS and CNS [117]. Epidemiological studies have indicated that neuropathic 
pain affects ~5% of all adults, resulting in about 3.75 million Americans suffering 
from this debilitating disease [117-119]. Numerous pharmacological and non-
pharmacological (e.g. aerobic exercise) therapy strategies have been developed 
to treat symptoms associated with neuropathic pain. Pharmacological therapy for 
neuropathic pain has had limited success [3, 4]; however, clinical studies have 
shown that exercise can reduce painful symptoms associated with fibromyalgia 
[27], chronic low back pain [29], and cancer treatment-related pain [120]. A 
survey by Warms et al., addressing the effectiveness of pharmacological and 
non-pharmacological therapies, reported that patients with a spinal cord injury 
rated regular exercise to be a more effective treatment for their neuropathic pain 
symptoms than any type of pain medication [26]. Thus, suggesting that exercise 
may be a viable therapy treatment to use in conjunction with other treatments 




Recently, we have shown that forced exercise (via swimming) reduced 
behavioral sensitivity (cold allodynia and thermal hyperalgesia) associated with 
peripheral nerve injury (peripheral sciatic nerve ligation) [30]; however, the 
exercise-induced mechanisms were not researched in this study. One potential 
mechanism under investigation includes increases in neurotrophic support, which 
have been shown to increase with exercise [31, 36-42]. In an animal model of 
neuropathic pain, aerobic exercise attenuated spinal cord injury-induced 
mechanical allodynia by restoring neurotrophic factors to baseline levels in the 
spinal cord [31]. Exercise has also been shown to induce gene changes in the 
spinal cord that promote neuronal survival (phosphatidylinositoal-3-kinase [PI3K]) 
[39], which is activated by glial cell line-derived neurotrophic factor (GDNF). 
Thus, exercise can have beneficial physiological effects, and increases in 
neurotrophic factors (via exercise) may be an alternative mechanism for reducing 
neuropathic pain. 
 
GDNF is important for modulating nociceptive signals during neuropathic 
pain states [72-75]. In the events following peripheral nerve injury, dysfunction of 
GDNF signaling in the nociceptive afferent system contributes to the 
development and/or maintenance of neuropathic pain. Aerobic exercise, a non-
pharmacological intervention, has been shown to alter GDNF expression in 
various neuronal and non-neuronal tissues [40, 88-90]. As shown by Dupont-
Versteegden et al. (2004), exercised animals exhibited an increase in functional 
recovery in spinal cord-injured rats, which were attributed to increases in GDNF 
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expression. Therefore, further studies are needed to determine whether the 
exercise-induced reductions in behavioral sensitivity exhibited in our peripheral 
nerve injured animals were also due to alterations in GDNF levels. To address 
this gap in knowledge, we evaluated changes in GDNF protein levels and 




Twenty-five 8 week old female Sprague-Dawley rats (weight range, 200 to 
250 g) were purchased from Charles Rivers Laboratories (Wilmington, MA) for 
both the 25 day and the 110 day study. The Institutional Animal Care and Use 
Committee of the University of Kansas Medical Center have approved the study 
protocol. One week prior to nerve injury surgery (acclimation period), rats 
randomized into the exercised groups were housed in cages with access to 
voluntary running wheels and rats randomized into the sedentary groups were 
housed in similar cages without running wheel access. During this acclimation 
period, rats in the exercised groups were allowed to participate in exercise 
voluntarily. Following the1 week acclimation period, rats within the sedentary and 
exercised groups underwent either the spared nerve injury (SNI) or sham 
surgery. Forty-eight hours after SNI or sham surgery, rats were returned to their 
respective cages. At the conclusion of each study, rats were sacrificed and the 




2.3.1.1 Short-term (25 day) study 
Sixteen rats were randomized into either the sedentary (Sed-Sham^25 
[n=4]) or exercised (Ex-Sham^25 [n=4]) sham surgery group or sedentary (Sed-
SNI^25 [n=4]) or exercised (Ex-SNI^25 [n=4]) SNI surgery group, which 
participated in the 25 day duration study. Behavioral assessments (mechanical 
allodynia [via von Frey monofilaments] and hyperalgesia [via pinprick]) were 
conducted immediately prior to the sham or SNI surgery, day 14, and 25 post 
sham or SNI surgery. 
 
2.3.1.2 Long-term (110 day) study 
Nine rats were randomized to either the sedentary (Sed-SNI^110 [n=4]) or 
exercised (Ex-SNI^110 [n=5]) SNI group, which participated in the 110 day 
duration study. Behavioral assessments (mechanical allodynia [via von Frey 
monofilaments] and hyperalgesia [via pinprick]) were conducted immediately 
prior to the SNI surgery, and at day 5, 8, 12, 15, 19, 22, 26, 29, 33, 36, 40, 47, 
50, 54, 57, 61, 64, 69, 89, 98, 103, and 110 after the SNI surgery. 
 
2.3.2 Spared nerve injury surgery 
Peripheral SNI was induced following baseline assessments of behavior 
measurements. The SNI procedure was conducted in accordance to Decosterd 
and Woolf (2000). Under isoflurane anesthesia, the skin on the lateral surface of 
the left thigh of the rat was shaved and incised revealing the muscle. Using 
forceps, a section was made directly through the bicep femoris muscle exposing 
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the sciatic nerve and its three terminal branches: the sural, common peroneal 
and tibial nerves. Thereafter, the tibial and common peroneal nerves were tightly 
ligated with 4.0 silk threads followed by axotomy, 2mm distal to the ligation. 
Considerable care was taken to avoid any contact with the intact sural nerve or 
stretching any of these three terminal branches. Muscle and skin was closed 
using 4.0 silk sutures. Sham surgery procedures were performed in a similar 
manner; however it only involved exposure of the sciatic nerve and its branches 
[4, 108, 109]. Animals were allowed 48 hours for recovery before placement into 
their respective cages. 
 
2.3.3 Voluntary exercise with free-access wheel running 
Exercised rats were individually housed in their own cages containing an 
exercise wheel (Mini Mitter Co. Inc., a Respironics Company, Bend, OR) so that 
all access would be completely voluntary. Each wheel revolution was 
continuously recorded and summarized in 30 minute intervals with the Vital View 
Data Acquisition System (Mini Mitter Co. Inc.) throughout the duration of the 
study. Sedentary rats were individually housed in their own cages that did not 
contain an exercise wheel. 
 
2.3.4 Behavioral measurements 
Mechanical allodynia and hyperalgesia were assessed via von Frey 
monofilaments and pinprick stimuli, respectively. All measurements were 
conducted on the lateral side of the left paw. After randomization, baseline 
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behavioral testing was performed on all rats followed by sham or SNI surgery. 
After 48 hours of recovery, rats were returned to their respective cages and 
behavioral testing was conducted at designated time points outlined in each 
study protocol. Rats predominately exercised from 6 p.m. to 6 a.m., so all 
scheduled behavioral assessments were conducted at least 4 hours after 6 a.m. 
in order to minimize known potential acute analgesic effects that exercise may 
have produced. Prior to each assessment, rats were acclimated for 1 hour in the 
testing environment (an inverted Plexiglas box on top of an elevated one-quarter 
inch stainless steel mesh floor). The order of testing included mechanical 
allodynia, followed by a 30 min window before assessing mechanical 
hyperalgesia. 
 
2.3.4.1 Mechanical allodynia 
A standard set of Semmes-Weinstein von Frey hairs (Stoelting, Wood 
Dale, IL), were used to touch the lateral part of the plantar surface of the paw. 
The threshold was taken as the lowest force (grams) that induced a withdrawal 
response to one of five repetitive stimuli [108, 121]. An interval time of 
approximately 30 seconds was used between stimuli. 
 
2.3.4.2 Mechanical hyperalgesia 
The pinprick test was performed on the lateral part of the plantar surface 
of the paw. The paw was briefly touched with the point of a pin at an intensity to 
indent but not penetrate the skin. Using a stopwatch, duration (seconds) of paw 
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withdrawal was recorded with a minimal value of 0.5 seconds or until the animal 
ceased reaction to the stimuli [108, 121]. 
 
2.3.5 Vaginal smears 
Responses to noxious stimuli have been reported to be influenced by the 
estrous cycle [122]. In order to ensure that our behavioral results were not 
skewed due to abnormal estrous cycling, daily vaginal smears were conducted. 
Briefly, the rat was gently held, the vagina was gently flushed once with saline 
and a drop of vaginal fluid was transferred to a clean, dry slide. Care was taken 
to not insert the dropper tip too deeply in the vagina, due to possibility of the rat 
becoming psuedopregnant. The sample was viewed using a standard power 
monocular microscope to view cells and to distinguish among the 4 phases: 1) 
diestrous, 2) proestrous, 3) estrous, and 4) metestrous [123]. 
 
2.3.6 Protein analysis by immunoblotting 
GDNF protein levels were examined in the lumbar region of the spinal 
cord using immunoblot analysis. We selected the lumbar region because this is 
the area in which nociceptive afferent fibers, that mediate painful sensations, 
terminate. The lumbar region of the spinal cord of each animal was collected 
during animal dissection and immediately frozen in liquid nitrogen, to preserve 
protein integrity, and stored at -80˚C until use. Tissues were homogenized using 
lysis buffer containing 137mM NaCl, 20mM Tris-HCl, pH 8.0, 1% nonyl 
phenoxylpolyethoxylethanol (NP-40), 10% glycerol, 1mM 
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phenylmethanesulfonylfluoride (PMSF), 10μg/ml aprotinin, 1μg/ml leupeptin, and 
0.5mM sodium vanadate. Tissue weight to buffer volume ratio was kept at 1:20 
(e.g. 400μl buffer per 20mg tissue). In the lysis buffer, tissues were homogenized 
using a glass Teflon homogenizer, and then centrifuged at +4˚C, at 16,000g for 
15 minutes. The supernatant was collected and total protein concentration was 
measured using BioRad protein assay reagent (BioRad Laboratories, Hercules, 
CA) in a 96 wellplate format, and  analyzed with the microplate reader MRXII 
(Dynex Technologies, Chantilly, VA) using bovine serum albumin as standard. 
Polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate 
was used to separate proteins in the supernatants. Twelve percent 
polyacrylamide gels with 15 wells for protein loading were poured using 
electrophoresis grade reagents. Twenty micrograms of total protein per sample 
was loaded per well of a gel, and proteins were separated under ~150-200 V 
current at constant voltage (30 mA). The separated proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane over night using sandwich tank 
transfer apparatus (Bio-Rad Laboratories). Membranes were blocked using a 
blocking buffer consisting of fresh 3% non-fat dry milk (BioRad Laboratories) 
suspended in phosphate buffered saline (PBS) with 0.1% Tween 20 (PBS-T) for 
1 hour. Membranes were then incubated with primary antibody (GDNF rabbit-
polyclonal [Santa Cruz Biotechnology, Santa Cruz, CA, catalog # sc-328; dilution 
1:2,000]) diluted in the blocking buffer, for 1 hour. The membrane was then 
washed 3 times with PBS-T for 10 minutes each. The membrane was then 
incubated for 30 minutes with the secondary antibody (goat anti-rabbit [Santa 
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Cruz Biotechnology, catalog # sc-2004; dilution 1:2,000]) in the blocking buffer 
and then washed 3 times in PBS-T for 10 minutes.  All membrane incubations 
and washes were done at room temperature on a shaker. Detection was 
achieved using enhanced chemiluminescent reagent (ECL; 
SuperSignalWestPico Chemiluminescent Substrate, catalog # 34080, Pierce, 
Rockford, IL]) according to manufacturer’s recommendations, and exposure of 
membranes to X-ray film. The relative levels of protein were estimated by 
measuring mean pixel intensity of protein bands using Adobe Photoshop. Before 
the blocking step, all membranes were stained with Ponceau S solution to verify 
even loading, integrity of the extracted proteins and proper transfer [124]. If 
uneven loading of protein occurred, a single band on the Ponceau stained 
membrane was used for normalization. GDNF was detected as a single band 
migrating at a molecular weight of 36 kilodaltons (kDa). The specificity of the 
band was confirmed using a GDNF blocking peptide (Santa Cruz Biotechnology, 
catalog #sc-328P). 
 
2.3.7 Data analysis 
Group comparisons of body weight, mechanical allodynia and 
hyperalgesia, and distance exercised were made using one-way analysis of 
variance (ANOVA) with repeated measures. Post hoc analysis was conducted 
using the least significant difference (L-S-D) method when appropriate. ANOVA 
was used to analyze GDNF protein levels between groups. Pearson Product 
Correlation was used to determine the relationship between changes in 
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mechanical allodynia and hyperalgesia and weekly distance exercised over the 
course of each study along with the relationship between GDNF protein levels 
and total distance exercised throughout the 25 and 110 day studies. Statistical 
significance was set at p≤0.05. All statistical analysis was done using Statistical 
Package for the Social Sciences (SPSS) version 17. Data are presented as 
mean ± standard error of the mean (SEM). 
 
2.4 Results 
2.4.1 Animal characteristics 
Throughout both studies (short- and long-term), all rats cycled normally, 
therefore testing did not disrupt the rats’ estrous cycle. The rat’s body weight is 
provided in Table 1. In the short-term study the Sed-Sham^25 group weighed 
significantly more than all other groups prior to surgery. Over the course of the 25 
day study, all rats had significantly gained weight, however there were no 
differences between groups at day 25. Weight gains by the Sed-Sham^25, Sed-
SNI^25, Ex-Sham^25, and Ex-SNI^25 groups increased by 30%, 33%, 28%, and 
26%, respectively. Body weight for the rats in the 110 day study did not differ 
among groups at anytime. By day 25, the Sed-SNI^110 and Ex- SNI^110 groups 






Table 2.1 Body weight of rats in the short- (25 day) and long-term (110 day) 
study. Prior to surgery the Sed-Sham^25 group weighed significantly more than 
all other groups in the short-term study. After surgery, all groups gained body 
throughout their respective studies and there were no differences between 
groups. There were no differences in body weight between the SNI groups in the 
long-term study. Prior to nerve injury (PNI). * = Sed-Sham^25 vs. Ex-Sham^25, 












  Body Weight (grams) 
Study Rat Group PNI Day 25 Day 110 
25 day Sedentary Sham 
(Sed-Sham^25) 
222 ± 4* 291 ± 12  
 Exercised Sham 
(Ex-Sham^25) 
205 ± 5 263 ± 10  
 Sedentary SNI 
(Sed-SNI^25) 
204 ± 4 273 ± 3  
 Exercised SNI 
(Ex-SNI^25) 
207 ± 4 260 ± 7  
     
     
110 day Sedentary SNI 
(Sed-SNI^110) 
222 ± 2 273 ± 10 357 ± 20 
 Exercised SNI 
(Ex-SNI^110) 





2.4.2 Daily exercise distance 
In the short-term study, the average daily exercise distance prior to 
surgery was 7.0±2.3 and 10.3±2.1 km/day, for the Ex-SNI^25 and Ex-Sham^25, 
respectively. Twenty-five days post surgery the Ex-SNI^25 and Ex-Sham^25 
groups ran 6.1±2.9 and 12.9±4.5 km/day, respectively (Figure 2.1). Although the 
Ex-Sham^25 group exercised more daily, there were no significant differences in 
exercised distance between or within groups over the 25 day training period. In 
the long-term study, the exercised group exercised on average 8.7±2.1 km/day 
prior to the surgery, whereas, 110 days post surgery they exercised significantly 
less at 4.9±0.5 km/day (Figure 2.2). 
 
2.4.3 Behavioral assessment (mechanical allodynia and hyperalgesia) 
2.4.3.1 Short-term (25 days) study 
Using an animal model of neuropathic pain, such as SNI, we evaluated 
the effects of long-term voluntary exercise on mechanical allodynia and 
hyperalgesia in rats following peripheral nerve injury. SNI surgery dramatically 
increased mechanical allodynia and hyperalgesia in both sedentary and 
exercised groups, which persisted throughout the remaining of the study (Figures 
2.3 and 2.4). At day 14, there were no differences in mechanical allodynia 
between SNI groups; however, at day 14 the Ex-SNI^25 group exhibited a 
decrease in mechanical hyperalgesia compared to the Sed-SNI^25 group 
(1.71±0.4 vs. 2.71±0.3 seconds, respectively). Compared to the Sed-SNI^25 
group, the Ex-SNI^25 group displayed a decrease in mechanical allodynia 
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Figure 2.1 Average daily exercise distance for the short-term (25 day) study. 
Prior to surgery the Ex-Sham^25 and Ex-SNI^25 groups exercised 10.3±2.1 and 
7.0±2.3 km/day, respectively. Four weeks post surgery they exercised 6.1±2.9 




























Figure 2.2 Average daily exercise distance for the long-term (110 day) study. 
Prior to nerve injury the Ex-SNI^110 exercised 8.7±2.1 km/ day; however, 110 
days post surgery they exercised significantly less at 4.9±0.5 km/day; however, 





Figure 2.2 Average daily exercise distance for the long-term (110 day) study.   






















Figure 2.3 Mechanical allodynia for the short-term (25 day) study. Exercised 
nerve-injured rats displayed a reduction in mechanical allodynia on the lateral 
side of paw compared to their sedentary counterpart. *=Sed-Sham^25 vs.Sed-






Figure 2.3 Mechanical allodynia for the short-term (25 day) study.   























Figure 2.4 Mechanical hyperalgesia for the short-term (25 day) study. Exercised 
nerve-injured rats displayed a reduction in mechanical hyperalgesia on the lateral 
side of paw compared to their sedentary counterpart. Between group 
comparisons; *=Sed-Sham^25 vs.Sed-SNI^25, †=Ex-Sham^25 vs. Ex-SNI^25, 
and ‡=Sed-SNI^25 vs. Ex-SNI^25. Within group comparison of Sed-SNI^25; 




Figure 2.4 Mechanical hyperalgesia for the short-term (25 day) study.   



























(0.5±0.2 vs. 1.8±0.1 grams, respectively) and hyperalgesia (3.7±0.2 vs. 1.3±0.2 
seconds, respectively) after 25 days of voluntary exercise. Within group 
comparisons showed no changes in mechanical allodynia between day 14 and 
25 after nerve injury in both sedentary and exercised SNI groups. However, Sed-
SNI^25 group exhibited a significant increase in hyperalgesia at day 14, which 
continued to increase through day 25, whereas, exercise ceased any further 
increases at day 25. Sham (control) group displayed no significant changes in 
behavioral hypersensitivity over the 25 day training period. There was no 
correlation with weekly distance exercised and change in behavioral sensitivity 
(mechanical allodynia and hyperalgesia) over time among the exercised group 
with SNI. 
 
2.4.3.2 Long-term (110 days) study 
In the short-term study, rats with SNI experienced reductions in behavioral 
sensitivity at day 14, which continued through day 25. To ascertain whether the 
effect of exercise was long-lasting, we evaluated the effects of exercise training 
extended to 110 days (approximately, 15 weeks) on mechanical allodynia and 
hyperalgesia in rats with peripheral nerve injury and their sedentary counterpart. 
Sham sedentary and exercised groups were not used for this study due to the 
fact that there were no changes in behavioral sensitivity in the 25 day study. After 
SNI surgery both sedentary and exercised groups displayed a marked increase 
in mechanical allodynia and hyperalgesia which persisted throughout the 110 day 
period (Figure 2.5). Similar to the 25 day study, voluntary exercise resulted 
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Figure 2.5 Mechanical allodynia for the long-term (110 day) study. Exercised 
nerve-injured rats displayed a reduction in mechanical allodynia on the lateral 





Figure 2.5 Mechanical allodynia for the long-term (110 day) study.   





























in a favorable change in pain behavior following nerve injury in these rats. The 
exercised group exhibited reductions in mechanical allodynia at 16 of the 22 time 
points assessed post nerve injury compared to the sedentary group. Similar to 
the 25 day study, rats in the exercised group exhibited beneficial reductions in 
mechanical hyperalgesia at day 22, and this trend remained throughout the study 
reaching statistical significance at day 110 (1.4±0.2 vs. 4.2±1.4 seconds, 
respectively) (Figure 2.6). Collectively, the 25 and 110 day studies support the 
use of voluntary exercise, which reduced behavioral symptoms following nerve 
injury in female rats. There was no correlation with weekly distance exercised 
and change in behavioral sensitivity (mechanical allodynia and hyperalgesia) 
over time among the exercised group with SNI. 
 
2.4.4 GDNF protein level analysis 
Observing the beneficial influence of exercise on behavioral sensitivity in 
rats with peripheral nerve injury, we sought to explore possible mechanisms 
involved and determined whether one of the essential neurotrophic growth 
factors, GDNF may be implicated. Immunoblotting was used to determine the 
effects voluntary exercise has on GDNF protein levels in the lumbar region spinal 
cord tissue. We found that 25 days post SNI surgery did not alter GDNF protein 
levels in the spinal cord compared to their respective control counterparts (Figure 
2.7). However, over time (110 days) GDNF levels significantly increased in the 
spinal cord of the SNI groups. The Sed-SNI^110 and Ex-SNI^110 groups 
exhibited a 2.3- and 1.6-fold increase in GDNF protein levels compared to the 
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Figure 2.6 Mechanical hyperalgesia for the long-term (110 day) study. Exercised 
nerve-injured rats displayed a reduction in mechanical hyperalgesia on the lateral 




Figure 2.6 Mechanical hyperalgesia for the long-term (110 day) study.   




















Figure 2.7 Immunoblot analysis of GDNF levels in the lumbar region of the spinal 
cord for the short-term (25 day) study. Upper panel shows representative 
immunoblot; lower panel shows histogram analysis of the immunoblot band 
intensity. 25 days post SNI surgery did not alter GDNF protein levels in the spinal 





Figure 2.7 Immunoblot analysis of GDNF levels in the lumbar region of the spinal 
cord for the short-term (25 day) study.   




















Sed-SNI^25 and Ex-SNI^25 groups, respectively (Figure 2.8). Twenty-five and 
110 days of voluntary exercise did not change GDNF protein levels in either 
exercised group. Thus, peripheral nerve injury increased GDNF protein levels in 
the spinal cord of the SNI groups, whereas voluntary exercise had no effect. In 
both studies, there was no correlation with total distance exercised and change in 
GDNF protein levels at day 25 or 110 among the exercised group with SNI. 
 
2.5 Discussion 
Our study is the first to report exercise-induced changes in mechanical 
hypersensitivity (mechanical allodynia and hyperalgesia) following nerve injury in 
female rats. We demonstrated that rats with peripheral nerve injury, which 
voluntarily exercised short (25 days) and long (110 days) terms, exhibited a 
statistical significant reduction in behavioral sensitivity. Alterations of GDNF 
levels in the lumbar region of the spinal cord were explored as a possible 
analgesic mechanism; however, voluntary exercise had no effect on GDNF. Our 
results support the hypothesis that long-term voluntary exercise reduces 
behavioral sensitivity in the setting of neuropathic pain. 
 
2.5.1 Reduction of mechanical sensitivity by exercise 
To make our current study more clinically relevant, our rats exercised 
voluntarily and behavioral sensitivity, such as mechanical allodynia and 
hyperalgesia, that neuropathic pain patients experience was assessed. In the 
current study, a model of neuropathic pain was adopted using the SNI model, 
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Figure 2.8 Immunoblot analysis of GDNF levels in the lumbar region of the spinal 
cord of the short- (25 day) and long-term (110 day) studies. Upper panel shows 
representative immunoblot; lower panel shows histogram analysis of the 
immunoblot band intensity. The sedentary and exercised groups in the long-term 
study exhibited a 2.3- and 1.6-fold increase in GDNF protein levels compared to 




Figure 2.8 Immunoblot analysis of GDNF levels in the lumbar region of the spinal 
cord of the short- (25 day) and long-term (110 day) studies.   






















which produces profound and reliable pain behaviors that closely mimic many 
features of clinical neuropathic pain [108]. Similar to the results reported by 
Decosterd and Woolf (2000), the SNI surgery produced an immediate onset (day 
5) of behavioral mechanical hypersensitivity, which persisted until the rats were 
sacrificed, suggesting it to be a valid animal model to replicate neuropathic pain. 
Previously, using the peripheral sciatic nerve ligation model we demonstrated 
that long-term exercise reduces behavioral sign of neuropathic pain after 18 to 25 
days [30]. Parallel to our previous study, in both of the present studies we were 
able to reproduce reductions in mechanical allodynia and hyperalgesia within the 
first 3 weeks of exercise training, which lasted up to 15 weeks. 
 
2.5.2 Mechanisms of exercise-induced analgesia 
Many potential mechanisms contribute to the pathogenesis of neuropathic 
pain, which occurs through changes in both the peripheral and central nervous 
systems. Mechanisms may include the redistribution or changes in sodium 
channels in the nerve or the sprouting of Aβ-fibers from lamina III/IV to lamina II 
of the dorsal horn. However, GDNF has been shown to regulate sodium 
channels [77] and decrease Aβ-fibers sprouting by promoting the survival of non-
peptidergic nociceptive C-fiber neurons (isolectin B4 [IB4] binding) [80], thus, 
ameliorating behavioral sensitivity associated with neuropathic pain [72, 76-79]. 




Increases in endogenous neurotrophins in the lumbar region of the spinal 
cord have been attributed to reducing mechanical allodynia in a model of central 
neuropathic pain involving spinal cord injury [31]. To gain insight into possible 
neurotrophic factor involvement in neuropathic pain, we assessed GDNF protein 
levels in the lumbar region of the spinal cord. Studies exploring the expression of 
GDNF in models of neuropathic pain have yielded contradictory results [72-75]. 
Nerve injury, via chronic constrictive injury and spinal nerve ligation, reduces 
GDNF expression in the dorsal root ganglion and sciatic nerve as early as 7 and 
14 days post surgery, respectively. Whereas, nerve transaction has shown to 
increase GDNF expression in the sciatic nerve 48 hours after denervation. This 
increase in GDNF expression can remain at high levels for at least 5 months 
after injury [75]. Contrary to these results, measured GDNF protein levels in the 
spinal cord were not altered 25 days after peripheral nerve injury in our study. 
However, over time (110 days) GDNF protein levels increased compared to 
levels at day 25 regardless of exercise intervention. We were unable to 
determine whether this increase in GDNF levels was due to the nerve injury or 
age because there were no sham control groups to compare to at this time 
period. Earlier studies demonstrated that GDNF can be affect by peripheral nerve 
injury as soon as 48 hours after nerve injury [75]. Therefore, a time course study 
should be explored to look at GDNF levels at earlier time points, which were 
described in earlier studies [72-75], in order to determine whether GDNF may 




Aerobic exercise has been shown to increase GDNF expression in 
neuronal (striatum) and non-neuronal (skeletal muscle) tissues [40, 88, 90]. In 
the spinal cord, initially, 25 days of voluntary exercise did not increase GDNF 
levels in either the sham or SNI group in our study. Parallel to the sedentary 
group, the exercised group exhibited an increase in GDNF protein levels at day 
110 following nerve injury; however there were no difference in GDNF levels 
between the sedentary and exercised groups at day 110. Therefore, a 
mechanism responsible for the exercise-induced reductions in behavioral 
sensitivity exhibited in rats experiencing neuropathic pain is not likely to involve 
the GDNF pathway and remains to be elucidated. Suggested mechanisms 
include the activation of the endogenous opioid system [32, 125] or increases in 
endogenous neurotrophins [31], which are the most commonly tested hypothesis 
in human and animal research. Endogenous opioids and neurotrophins act as a 
central modulator of pain [34, 126], thereby reducing symptoms associated with 
neuropathic pain. 
 
The SNI model induces robust behavioral modifications, which leads to 
sensory and motor deficits [108]. These deficits caused by nerve injuries can be 
compensated by the reinnervation of denervated targets by regeneration of 
injured axons [127]. Exercise has been shown to increase regeneration of 
sensory [128] and motor neurons [129], which correlates with the distance the 
animals exercised [128]. Van Meeteren et al. (1997) demonstrated that exercise 
can significantly improve sensory and motor function during the early phase of 
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nerve regeneration (within 2 to 3 weeks), which persisted throughout the 
remainder of the study (150 days) [130]. These findings are similar to the time 
period that our animals exhibited reduction in mechanical sensitivity. Molteni et 
al. (2004) reported that exercised-induced axonal regeneration was consistent 
with the rise in neurotrophins (BDNF and NT-3). They believe that activation of 
the neurotrophin signal transduction pathways during exercise may play a critical 
role promoting axonal growth [128]. Thus, enhanced nerve regeneration due to 
increases in neurotrophins, which have been shown to increase with exercise 
[31, 36-42], may be another potential mechanism for the exercise-induced 
reductions in mechanical sensitivity. 
 
2.5.3 Clinical implications 
The overall goal of pain management is returning the individual to a 
productive life. Patients typically receive a multimodal approach of 
pharmacological and non-pharmacological interventions for pain management 
[131]. As reported, pharmacological interventions are not always effective in 
managing the patient’s neuropathic pain [3, 4]. The use of non-pharmacological 
interventions, such as exercise is gaining momentum. In a survey, 72% of 
practitioners, which were members of the International Association for the Study 
of Pain, recommend the use of exercise to their patients in order to treat 
neuropathic pain symptoms. Of these practitioners, 80% believed that exercise 
should be part of legitimate medical practice [25]. Our results support the idea 
that long-term exercise can be considered to complement current treatment 
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strategies aimed at attenuating neuropathic pain. However, according to the 
survey by Berman and Bausell (2000), only 59% of practitioners reported having 
sufficient knowledge to discuss the use of exercise as a therapy treatment with 
their patients. Therefore, knowledge of the effectiveness of exercise for treating 
neuropathic pain related symptoms is clearly warranted. 
 
2.5.4 Conclusion 
A 30% reduction in pain has been shown to be clinically important [131, 
132]. Given the diversity of neuropathic pain mechanisms, patient responses, 
and diseases, no single pharmacological intervention is effective; therefore 
treatments must be individualized and managed with a multidisciplinary 
approach. When considering the strategy for managing neuropathic pain, 
treatments with the lowest risk for adverse effects should be considered first. 
Evidence supporting exercise for treating neuropathic pain is limited; however 
given its presumed safety, exercise should be considered whenever appropriate 
[131]. 
 
Results obtained from our study, demonstrate the ability of voluntary 
exercise to attenuate the severity of behavioral hypersensitivity to mechanical 
stimuli following nerve injury in female rats. Voluntary exercise did not alter 
GDNF protein levels in the spinal cord, therefore other mechanisms may be 
involved in reducing mechanical allodynia and hyperalgesia exhibited by the 
exercised rats. The present study will set the foundation for future studies 
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examining how exercise affects behavioral sensitivity in other persistent pain 
models (e.g. diabetic neuropathy), with the goal of potentially limiting the 



















Effect of voluntary exercise on mechanical allodynia and glial cell line-




Diabetic neuropathy (DN) is the most common type of neuropathy 
worldwide. Growth factor deficiency (e.g. glial cell-derived neurotrophic factor 
[GDNF]) is one of the main aetiologies of DN. Aerobic exercise has been shown 
to reduce behavioral sensitivity by increasing neurotrophin production. However, 
the ability of exercise to reduce complications of DN (e.g. mechanical allodynia) 
and alter GDNF levels has yet to be explored. The purpose of this study is to 
determine how diabetes affects GDNF levels and whether voluntary exercise has 
any influence in order to attenuate or delay the behavioral sensitivity associated 
with DN. Sixteen Sprague Dawley rats were rats were randomized into one of 
four groups (4 rats per group): 1) sedentary non-diabetic control (Sed-C), 2.) 
exercised non-diabetic control (Ex-C), 3) sedentary diabetic (Sed-D), and 4) 
exercised diabetic (Ex-D). The rats in the diabetic groups received streptozotocin 
(STZ)-injections to induce diabetes followed by insulin pellet implantation. Both 
exercised groups had access to voluntary running wheels. To quantify DN, 
mechanical allodynia (assessed via von Frey filaments) was measured prior to 
STZ-injections and twice a week for 8 weeks following injections. GDNF protein 
levels were examined in the lumbar region of the spinal cord using immunoblot 
analysis. After 8 weeks of voluntary exercise, the Ex-D (7.4g) group exhibited 
significantly higher mechanical thresholds compared to Sed-D (2.9g), suggesting 
a favorable response to exercise. There were no changes in GDNF expression 
between the sedentary groups; however 8 weeks of exercise increased GDNF 
protein expression in both exercised groups compared to their sedentary 
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counterparts. GDNF protein in the dorsal or ventral spinal cord of exercised 
diabetic rats revealed that the greatest increases in GDNF protein occurred in the 
ventral horn. Voluntary exercise decreased mechanical allodynia and this 
reduction may be due to an increase in GDNF, which may be exerting its 
analgesic effects in the ventral horn of the lumbar region of the spinal cord. Thus, 
this study supports the use of voluntary exercise to complement current 





Peripheral neuropathy is a common complication associated with 
diabetes, with more than half of patients who have Type 1 and 2 diabetes 
experiencing neuropathic complications [47]. Of these patients, 15% to 30% 
suffer from painful diabetic neuropathy, whereas the remainder experiences a 
negative phenomenon, such as numbness [48]. Diabetic neuropathy (DN) is 
associated with structural changes in the peripheral nerve that includes axonal 
atrophy, demyelination, loss of nerve fibers, and the blunted regeneration of the 
nerve fibers [52, 53]. Clinical symptoms associated with DN involve poor gait and 
balance associated with large sensory fibers, and abnormal cold and/or heat 
sensation associated with small sensory fibers. Chronic pain associated with 
diabetes is represented by hyperalgesia, allodynia, parethesias and spontaneous 
pain [49, 50]. Despite its frequency and considerable disability, the management 
for DN remains unsatisfactory. As a result, there is an unmet clinical need and an 
ongoing challenge to develop more effective therapies [133]. 
 
Persistent pain caused by DN often responds poorly to pharmacological 
interventions. As a non-pharmacological approach, we have recently shown that 
forced exercise (via swimming) reduces behavioral sensitivity (cold allodynia and 
thermal hyperalgesia) in an animal model of neuropathic pain (peripheral sciatic 
nerve ligation) [30]. Exercise has long been recognized as a part of therapy in the 
management of diabetes, yet 31% of type 2 diabetic patients fail to participate in 
basic physical activity [134] possibly due to secondary diabetic complications (i.e. 
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DN). The ability of exercise to prevent the onset of painful diabetic neuropathy in 
individuals without signs and symptoms of DN has been reported [60]; however, 
the efficacy of exercise exerting a similar effect in individuals with signs and 
symptoms of DN has yet to be explored. 
 
Growth factor deficiency is one of the main aetiologies of DN [53]. Recent 
studies have reported that diabetes alters the expression of GDNF expression in 
various central and peripheral tissues [86, 135]. GDNF is well known to play an 
important role in the modulation of nociceptive signals especially during 
neuropathic pain states [72, 73, 78]. In addition, studies have shown that aerobic 
exercise can increase GDNF in skeletal muscle of healthy and spinal-injured 
animals [88, 90]. In spinal-injured rats, it was postulated that the release of 
GDNF from exercised muscles may be involved in spinal cord plasticity following 
injury and increased GDNF in the periphery can be transported centrally to exert 
its neurotrophic actions on spinal cord cells [88]. 
 
Here, experiments were performed in diabetic rats to test whether 
exercise can attenuate painful sensory symptoms associated with diabetes. Our 
results suggest that exercise can exert beneficial actions on painful DN, and 








Sixteen 8 week old Sprague-Dawley female rats with initial body weight of 
200-250 grams were purchased from Charles River (Wilmington, MA). Rats were 
randomized into one of four groups (4 rats per group): 1) sedentary non-diabetic 
control (Sed-C), 2.) exercised non-diabetic control (Ex-C), 3) sedentary diabetic 
(Sed-D), and 4) exercised diabetic (Ex-D). After randomization, control rats were 
injected with 0.4 ml of sodium citrate buffer and diabetic rats were made diabetic 
by a single injection of streptozotocin (STZ), a toxin that destroys pancreatic beta 
islets, thus causing hyperglycemia and diabetes. This is a widely used model of 
type 1 diabetes [116], which mimics many chronic complications observed in 
human diabetic, such as DN [111]. Mechanical allodynia (via von Frey 
monofilaments) was assessed prior to injections and twice a week for 8 weeks. 
After injections all rats in the exercised groups were placed in cages with access 
to voluntary running wheels and sedentary rats were placed in cages without 
running wheel access. Eight weeks after injections peak volume of oxygen 
(VO2peak) was measured to assess cardiorespiratory fitness. After the 8 week 
intervention rats were over-anesthetized with Nembutal and the lumbar region of 
the spinal cord was harvested for GDNF protein analysis. 
 
3.3.2 Behavioral measurements: mechanical allodynia 
After randomization, baseline assessments were performed on all rats 
followed by STZ- or vehicle-injections. Rats predominately exercised from 6 p.m. 
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to 6 a.m., so all scheduled behavioral assessments were conducted at least 4 
hours after 6 a.m. in order to minimize known potential acute analgesic effects 
that exercise may have produced. Prior to each assessment, rats were 
acclimated for 1 hour in the testing environment (an inverted Plexiglas box on top 
of an elevated one-quarter inch stainless steel mesh floor). A standard set of 
Semmes-Weinstein von Frey hairs (Stoelting, Wood Dale, IL), which are a series 
of nylon monofilaments of increasing stiffness that apply defined levels of force 
(grams) as they are pressed to the point where they bend, was applied in 
sequence to the plantar surface of the left hind paw. Starting with the filament 
that possesses a buckling weight of 2.0 g, a positive response is recorded after 
lifting of the paw and the next lightest filament is used for the next measurement. 
Absence of a response after 5 seconds, the next filament of increasing weight 
was used. This procedure continued until four measurements had been made 
after an initial change in the behavior or until five consecutive negative (given the 
score of 15 g) or four positive (score of 0.25 g) scores occur [136]. 
 
3.3.3 Induction of diabetes 
All rats assigned to the diabetic groups were made diabetic by a single 
intraperitoneal (i.p.) injection of STZ (50 mg/kg body weight, freshly dissolved in 
10mM sodium citrate, pH 4.5, with 0.9% NaCl), whereas the control rats were 
injected with 0.4 ml of sodium citrate buffer. Typically, 2 days later, diabetes was 
confirmed by measuring glucose concentration in a blood sample obtained by a 
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tail prick using a glucometer (Accu-Check Active; Rosche Diagnostics, 
Indianapolis, IN). 
 
3.3.4 Insulin treatment 
Diabetic rats were treated with low dose of insulin to maintain body weight 
with persistent hyperglycemia. One week after STZ-injections rats in the diabetic 
groups were implanted with a 2.5-mm segment of an insulin capsule (cut down 
from the 7.0-mm length [results in persistent hyperglycemia] Linplant sustained 
release insulin capsule; Linshin, Scarborough, Ont. Canada) placed 
subcutaneous at the scruff of the neck. Under isoflurane anesthesia, the scruff of 
the neck was shaved and the skin was pierced with a 16 gauge disposable 
hypodermic needle and withdrawn. The trocar was then pushed through the 
skin’s orifice just created by the needle. The implant was inserted into the 
proximal end of the trocar. Using the stylet the implant was pushed until it exits 
from the distal end of the inserted trocar. Blood glucose levels were tested 
weekly after implantation to ensure that the rat remains hyperglycemic, and body 
weight was monitored weekly. If the body weight for the hyperglycemic animal 
drops below 20% of starting weight, a new 2.5-mm segment of capsule was 
inserted. 
 
3.3.5 Vaginal smears 
Estrous cycle was assessed to determine whether our rats were 
menstruating normally throughout the experiment. To monitor the rat’s estrous 
94 
 
cycle, daily vaginal smears were performed. Briefly, the rats were grasped from 
behind its head. With a medicine dropper containing two drops of saline, the 
vagina will be gently flushed once and a drop of vaginal fluid was transferred to a 
clean, dry slide. Care was taken to not insert the dropper tip too deeply in the 
vagina, due to possibility of the rat becoming psuedopregnant. The slide was 
placed under a low power monocular microscope to view cells. The estrous cycle 
of a rat consists of 4 phases: 1) diestrous, 2) proestrous, 3) estrous, and 4) 
metestrous. The diestrous smear consisted of mainly leucocytes and some 
epithelial cells. The number of nucleated epithelial cells increases during 
proestrous and early estrous; leucocytes disappear. In full estrous, the smear 
consisted entirely of large cornified epithelial cells. Leucocytes appear again in 
metestrous, together with some remaining cornified epithelial cells [123]. 
 
3.3.6 Voluntary exercise with free-access wheel running 
Exercised rats were individually housed in their own cage containing an 
exercise wheel (Mini Mitter Co. Inc., a Respironics Company, Bend, OR), thus, 
all exercise was voluntary. Each wheel revolution was continuously recorded and 
summarized in 30 minute intervals with the Vital View Data Acquisition System 
(Mini Mitter Co. Inc.) throughout the duration of the study. Sedentary rats were 
individually housed in their own cage that does not contain an exercise wheel; 
however they were exposed to a noise from running wheels as the cages with 




3.3.7 Calorimetry for VO2peak measurements 
Cardiorespiratory capacity was measured using an indirect calorimetry 
after 8 weeks of exercise training. Indirect calorimetries were carried out using an 
open circuit small animal calorimeter (Eco-Oxymax) attached to an enclosed 
modular treadmill (both from Columbus Instruments, Columbus, OH). Each trial 
measured oxygen consumption (VO2 ml/kg/hr), respiratory exchange ratio (RER), 
and heat production (kcal/hr) during the resting and exercise phases. Fresh 
ambient air was drawn through the chamber at a flow rate of 2 L/min during the 
resting phase (first 10 intervals) and at 3.5 L/min during the exercise phase 
(remainder of test). The treadmill was started at a speed of 10 meters/min, 0 º 
grades. Every five intervals the speed was increase by 5 meters/min. The test 
stopped when the animal was no longer able to run. 
 
3.3.8 Protein analysis 
GDNF protein levels were examined in the lumbar region of the spinal 
cord using immunoblot analysis. We selected the lumbar region because this is 
the area in which nociceptive afferent fibers that mediate painful sensations 
terminate. The lumbar region of the spinal cord of each animal was collected 
during animal dissection and immediately frozen in liquid nitrogen, to preserve 
protein integrity, and stored at -80˚C until use. Tissues were homogenized using 
lysis buffer containing 137mM NaCl, 20mM Tris-HCl, pH 8.0, 1% nonyl 
phenoxylpolyethoxylethanol (NP-40), 10% glycerol, 1mM 
phenylmethanesulfonylfluoride (PMSF), 10μg/ml aprotinin, 1μg/ml leupeptin, and 
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0.5mM sodium vanadate. Tissue weight to buffer volume ratio was kept at 1:20 
(e.g. 400μl buffer per 20mg tissue). In the lysis buffer, tissues were homogenized 
using a glass Teflon homogenizer, and then centrifuged at +4˚C, at 16,000g for 
15 minutes. The supernatant was collected and total protein concentration was 
measured using BioRad protein assay reagent (BioRad Laboratories, Hercules, 
CA) in a 96 wellplate format, and  analyzed with the microplate reader MRXII 
(Dynex Technologies, Chantilly, VA) using bovine serum albumin as standard. 
Polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate 
was used to separate proteins in the supernatants. Fourteen percent 
polyacrylamide gels with 15 wells for protein loading were poured using 
electrophoresis grade reagents. Twenty micrograms of total protein per sample 
was loaded per well of a gel, and proteins were separated under ~150-200 V 
current at constant voltage (30 mA). The separated proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane over night using sandwich tank 
transfer apparatus (Bio-Rad Laboratories). Membranes were blocked using a 
blocking buffer consisting of fresh 3% non-fat dry milk (BioRad Laboratories) 
suspended in phosphate buffered saline (PBS) with 0.1% Tween 20 (PBS-T) for 
1 hour. Membranes were then incubated with primary antibody (GDNF rabbit-
polyclonal [Santa Cruz Biotechnology, Santa Cruz, CA, catalog # sc-328; dilution 
1:2,000]) diluted in the blocking buffer, for 1 hour. The membrane was then 
washed 3 times with PBS-T for 10 minutes each. The membrane was then 
incubated for 30 minutes with the secondary antibody (goat anti-rabbit [Santa 
Cruz Biotechnology, catalog # sc-2004; dilution 1:2,000]) in the blocking buffer 
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and then washed 3 times in PBS-T for 10 minutes.  All membrane incubations 
and washes were done at room temperature on a shaker. Detection was 
achieved using enhanced chemiluminescent reagent (ECL; 
SuperSignalWestPico Chemiluminescent Substrate, catalog # 34080, Pierce, 
Rockford, IL]) according to manufacturer’s recommendations, and exposure of 
membranes to X-ray film. The relative levels of protein were estimated by 
measuring mean pixel intensity of protein bands using Adobe Photoshop. Before 
the blocking step, all membranes were stained with Ponceau S solution to verify 
even loading, integrity of the extracted proteins and proper transfer [124]. If 
uneven loading of protein occurred, a single band on the Ponceau stained 
membrane was used for normalization. GDNF was detected as a single band 
migrating at a molecular weight of 36 kilodaltons (kDa). The specificity of the 
band was confirmed using a GDNF blocking peptide (Santa Cruz Biotechnology, 
catalog #sc-328P). 
 
3.3.9 Data analysis 
For protein analysis and VO2peak an analysis of variance (ANOVA) with a 
least significant difference (L-S-D) post hoc analysis was conducted for 
identification of significant differences between groups. Mechanical allodynia and 
daily exercise distance were analyzed using repeated measures ANOVA with a 
LSD post hoc analysis conducted for identification of significant differences within 
and between time and groups. Independent samples t-test was used to analyze 
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GDNF protein levels within groups. Significance was set at 0.05 (p<.05). Data are 
presented as mean ± standard error of the mean (SEM). 
 
3.4 Results 
3.4.1 Animal characteristics 
Blood glucose for the sedentary and exercised non-diabetic groups did not 
change over the 8 week experiment (136±8 vs. 127±4 mg/dL, respectively, at 
day 56). After STZ-injections the diabetic groups had marked increase in blood 
glucose compared to their respective control group, which persisted throughout 
the 8 week study. Exercised diabetic animals exhibited an improvement in blood 
glucose at day 14 (1 week after inserting the insulin pellet) compared to their 
sedentary counterpart, which diminished during the remainder of the study 
(276±65 vs. 348±70 mg/dL, respectively, at day 56). After insertion of the insulin 
pellet the, Ex-D group’s blood glucose was similar to the Ex-C group; however by 
day 49 the Ex-D group’s blood glucose had returned to hyperglycemic levels 
where it remained until the end of the study (Figure 3.1). 
 
Over the 8 week study, all groups exhibited an increase in body weight. 
The Sed-C, Ex-C, Sed-D, and Ex-D groups showed a 63.7%, 55.1%, 23.6%, and 
40.9% increase in body weight over the 8 week experiment, respectively. There 
were no differences in body weight between the diabetic groups (Sed-D vs. Ex-D 
[278±13 vs. 300±14 grams, at day 56]) and exercised groups (Ex-C vs. Ex-D 
[297±15 vs. 300±14 grams, at day 56]) throughout the study. However, the body 
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Figure 3.1 Blood glucose levels in rats throughout the 8 week training program. 
Insulin pellet was inserted at day 7 post STZ-injection. STZ-injections markedly 
increase in blood glucose in the diabetic groups compared to their respective 
control groups, which persisted throughout the 8 week study. Exercised diabetic 
animals exhibited an improvement in blood glucose at day 14 (1 week after 
inserting the insulin pellet) compared to their sedentary counterpart, which 
diminished during the remainder of the study (276±65 vs. 348±70 mg/dL], 





Figure 3.1 Blood glucose levels in rats throughout the 8 week training program.   




























weight of the Sed-C (352±27 grams [at day 56]) group was significantly greater 
during the majority of the study compared to the Ex-C (297±15 grams [at day 56]) 
and Sed-D (278±13 grams [at day 56]) groups (Figure 3.2). 
 
3.4.2 Maximal metabolic measurements 
To quantify the effect of exercise, VO2peak was evaluated. As shown in 
Figure 3.3, at the end of 8 weeks, cardiorespiratory capacity did not significantly 
differ between the Ex-D and Sed-D groups; however, the Ex-D group 
demonstrated favorable trend (3196 vs. 2890 ml/kg/hr, respectively). Ex-C 
significantly differed from Sed-C (3389 vs. 2758 ml/kg/hr, respectively) possibly 
because the Ex-C group on average exercised more than Ex-D group, which 
reached significance during week 7 (Figure 3.4). 
 
3.4.3 Behavioral assessments 
We evaluated the effects of habitual exercise on mechanical allodynia in 
diabetic rats that developed mechanical allodynia and their respective controls 
(Figure 3.5). After STZ-injections both diabetic groups exhibited an increase in 
mechanical allodynia. The Sed-D group continued to exhibit an increase in 
mechanical allodynia throughout the remainder of the 8 week study. Exercise 
caused a favorable change in pain behavior following STZ-induced diabetes in 
these rats. At day 56 mechanical allodynia was significantly less in the Ex-D 
compared to the Sed-D group (7.4±1.7 vs. 2.9±0.6 grams, respectively). Among 
non-diabetic groups, the Sed-C group exhibited greater levels in mechanical 
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Figure 3.2 Body weight of rats throughout the 8 week training program. Insulin 
pellet was inserted at day 7 post STZ-injection. The Sed-C, Ex-C, Sed-D, and 
Ex-D groups showed a 63.7%, 55.1%, 23.6%, and 40.9% increase in body 
weight over the 8 week experiment, respectively. Body weight of the Sed-C 
(352±27 grams [at day 56]) group was significantly greater during the majority of 
the study compared to the Ex-C (297±15 grams [at day 56]) and Sed-D (278±13 





Figure 3.2 Body weight of rats throughout the 8 week training program.   





























Figure 3.3 Peak volume of oxygen uptake (VO2 [an index of cardiorespiratory 
fitness]) in exercised and sedentary rats at 8 weeks. At 8 weeks, Ex-C 
significantly differed from Sed-C (3389 vs. 2758 ml/kg/hr, respectively), while the 
Ex-D group demonstrated a similar trend compared to the Sed-D group (3196 vs. 




































Figure 3.4 Average daily exercise distance throughout the 8 week training 
program. During week 8 the Ex-C and Ex-D groups exercised 10.2±1.7 and 





Figure 3.4 Average daily exercise distance throughout the 8 week training 
program.  






















Figure 3.5 Mechanical allodynia assessed using a von Frey monofilament test 
56 days post STZ-injection. Insulin pellet was inserted at day 7 post STZ-
injection. At day 56 von Frey (force [g]) assessments were significantly different 
between the Ex-D and Sed-D group (7.4±1.7 vs. 2.9±0.6, respectively). *=Sed-C 




Figure 3.5 Mechanical allodynia assessed using a von Frey monofilament test 56 
days post STZ-injection.  










































thresholds compared to the Ex-C group at day 56 (12.5±1.7 vs. 5.9±2.1 grams, 
respectively). However, 8 weeks of exercise in STZ-induced diabetic rats 
resulted in decreases in mechanical allodynia. 
 
3.4.4 Protein analysis 
Protein analysis was used to determine the effects voluntary exercise has 
on GDNF (via immunoblotting) protein levels in the lumbar region in rat spinal 
cord and dorsal and ventral horn of spinal cord tissue. 
 
3.4.4.1 Whole lumbar region of the spinal cord 
Eight weeks of diabetes did not affect GDNF proteins levels in the spinal 
cord compared to its sedentary control (Figure 3.6). However, voluntary exercise 
increased GDNF protein levels among both exercised groups. The Ex-D and Ex-
C group displayed a 3.2- and 1.5-fold increase in GDNF protein levels compared 
to their sedentary counterparts, respectively. Thus, diabetes did not cause 
changes in GDNF protein levels, while exercise training increased its level in 
both diabetic and control groups. 
 
3.4.4.2 Dorsal and ventral horn of spinal cord 
To assess where GDNF is exerting its analgesic effects in the spinal cord, we 
examined protein levels in the dorsal and ventral horn of the lumbar region of the 
spinal cord. There were no changes in GDNF protein levels in the dorsal horn 
among either control or diabetic groups (Figure 3.7). However, diabetes 
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Figure 3.6 Immunoblot analysis of GDNF levels in the lumbar region of the spinal 
cord of non-diabetic and diabetic rats. Upper panel shows representative 
immunoblot; lower panel shows histogram analysis of the immunoblot. A.) 
sedentary groups, B.) control groups, and C.) diabetic groups. There were no 
differences between either sedentary groups. Both exercised groups 
demonstrated an increase in GDNF levels compared to their sedentary 





Figure 3.6 Immunoblot analysis of GDNF levels in the lumbar region of the spinal 
























































Figure 3.7 Dorsal horn and ventral horn. Immunoblot analysis of GDNF levels in 
the dorsal horn of the lumbar region of the spinal cord of non-diabetic and 
diabetic rats. Upper panel shows representative immunoblot; lower panel shows 
histogram analysis of the immunoblot. A.) dorsal horn and B.) ventral horn. There 
were no differences in GDNF levels in the dorsal horn between groups. Diabetes 
significantly decreased GDNF levels in the ventral horn of both diabetic groups 




Figure 3.7 Dorsal horn and ventral horn. 
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significantly decreased GDNF protein levels in the ventral horn. The Sed-D and 
Ex-D groups exhibited a 3.5- and 3.0-fold decrease in GDNF levels in the ventral 
horn compared to respective controls, respectively. Exercise had no effect on 
GDNF protein levels in the dorsal or ventral horn in either the diabetic or control 
group. Within group comparisons showed that GDNF levels did not differ 
between dorsal and ventral horn of the control groups (Figure 3.8). However, in 
both diabetic groups GDNF proteins levels were significantly higher in the ventral 
horn compared to the dorsal horn. GDNF protein levels in the ventral horn of the 
Sed-D and Ex-D groups’ was 1.4- and 3.4-fold greater compared to levels in the 
dorsal horn. These results suggest that the GDNF is may be exerting its 
analgesic effects in the ventral horn of the lumbar region of the spinal cord. 
 
3.5 Discussion 
Painful diabetic neuropathy is a prominent clinical problem with few 
treatment options. Here, we have tested the ability of voluntary exercise to 
improve pain indices in diabetic rats. Our results suggest that voluntary exercise 
significantly improves mechanical hypersensitivity in diabetic rats. Moreover, our 
studies suggest that these analgesic actions may be mediated by exercise-
induced increases in neurotrophic factor levels. Voluntary exercise significantly 
increased GDNF protein levels in the spinal cord. This study strongly suggest 
that exercise has beneficial actions on alleviating pain in diabetic patients and 
provide a potential mechanism by which exercise changes neurotrophic factor 
levels that are beneficial to neural pain circuitry. 
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Figure 3.8 Dorsal horn versus ventral horn. Immunoblot analysis of GDNF levels 
in the dorsal and ventral horn of the lumbar region of the spinal cord of non-
diabetic and diabetic rats. Upper panel shows representative immunoblot; lower 
panel shows histogram analysis of the immunoblot. A.) Sed-C, B.) Ex-C, C.) Sed-
D, and D.) Ex-D. GDNF levels did not differ between the ventral horn versus the 
dorsal horn among both control groups. Diabetes significantly increased GDNF 
levels in the ventral horn compared to the dorsal horn among the sedentary and 
exercised diabetic groups (1.4- and 3.4-fold increase, respectively). * p<0.05 
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Figure 3.8 Dorsal horn versus ventral horn. 
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3.5.1 Exercise reduces diabetes-induced mechanical allodynia 
Painful diabetic neuropathy is primarily associated with burning, 
spontaneous pain in the extremities, although mechanical allodynia is also 
generally present. To date, best approach to study painful neuropathy in rodents 
is assessment of mechanical sensitivity using monofilaments. This is in large part 
due to the inability to assess or detect spontaneous pain in rodents. Sprague 
Dawley rats are well known as a model of diabetes-induced mechanical allodynia 
[116]. In the current study, diabetic Sprague Dawley rats develop significant 
mechanical allodynia within 3 weeks of diabetes onset, which persisted 
throughout the 8 week study. 
 
An important focus of this study was to test whether voluntary exercise 
could modify the increased pain sensitivity of diabetic rats. In diabetic patients 
without any signs of symptoms of DN, exercise can delay the development of 
motor and sensory neuropathy [60]. Currently, there is limited knowledge about 
the effectiveness exercise has on attenuating neuropathy associate with DN. To 
gap this knowledge we have shown that, long-term voluntary exercise reduces 
mechanical allodynia in diabetic rats. Diabetic rats showed transient development 
of mechanical allodynia; however 17-days of exercise returned mechanical 
thresholds to baseline levels in the diabetic group, which persisted throughout 
the 8 week experiment. Although not tested, it would be interesting to determine 
if exercise interventions were terminated whether diabetic rodents would again 
develop mechanical allodynia. It is important to point out that our results only 
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address pain associated with diabetes. We have shown that the administration of 
GDNF can improve mechanical and inflammatory (formalin) behavioral sensitivity 
in diabetic mice with insensate DN [137]. Whether exercise can improve 
insensate neuropathy in non-painful models remains unknown. It will be 
interesting to determine which various aspects of diabetic neuropathy can be 
modified by exercise. 
 
3.5.2 Mechanisms of exercise-induced analgesia 
Understanding the molecular mechanisms by which exercise exerts 
actions on peripheral nerve function remains poorly understood. Putative 
mechanisms likely include involvement of both opioid and non-opioid systems. 
Exercise-induced release of endogenous opioids is the most commonly tested 
and proposed mechanism for exercise induced analgesia in healthy individuals 
[125]. In an animal model of neuropathic pain via spinal cord injury, the 
amelioration of mechanical allodynia has been attributed to an increase in 
neurotrophins in the lumbar region of the spinal cord and soleus muscle [31]. 
 
Deprivation of neurotrophic factor support contributes to the pathogenesis 
of DN [54]. Liu et al. (2009) demonstrated that neuropathic symptoms in diabetic 
rats correlated with the levels of GDNF expression. As GDNF expression in the 
sciatic nerve diminished neuropathic symptoms increased; however, after GDNF 
gene delivery, these neuropathic symptoms were alleviated. GDNF is important 
for regulating cell survival, differentiation, proliferation, migration, chemotaxis, 
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branching morphogenesis, neurite outgrowth, and synaptic plasticity [63, 64] and 
is also known to have potent analgesic effects in neuropathic pain states [72, 76-
79]. Therefore, as a possible mechanism for reducing mechanical allodynia in 
diabetic rats, we assessed GDNF protein levels in the lumbar region of the spinal 
cord. Voluntary exercise dramatically increased GDNF protein levels in lumbar 
spinal cord of diabetic rats. Western blots of GDNF protein in the dorsal and 
ventral spinal cord of exercised diabetic rats revealed that the greatest increases 
in GDNF protein occurred in the ventral horn, suggesting that motoneurons may 
play an important role in modulating mechanical allodynia in diabetic rats. 
Increases in mechanical allodynia exhibited by the sedentary diabetic group 
cannot be attributed to alterations in neurotrophic support; however increases in 
GDNF via voluntary exercise may have a therapeutic effect. Possible 
mechanisms for these analgesic actions by GDNF include promoting the survival 
of non-peptidergic nociceptive C-fiber neurons (isolectin B4 [IB4] binding), 
therefore decreasing Aβ-fiber sprouting [80], regulating sodium channel 
expression [77], and by regulating neuropeptides expression [76]. Thus, this 
study demonstrated that exercise causes a favorable change in mechanical 
allodynia in female rats with diabetes. These results strongly argue that GDNF 
may be a viable treatment for attenuating acute and chronic pain states 






3.5.3 Clinical implications 
Exercise has long been used to manage diabetes. Exercise has been 
shown to lower glucose levels and improve insulin action. In diabetic patients 
with less extreme glucose levels, exercise can improve insulin sensitivity and 
glucose disposal. Also, aerobic exercise can improve cardiorespiratory fitness 
(VO2max), thus reducing the risk of developing cardiovascular diseases, including 
coronary heart disease, stroke, peripheral vascular disease, and congestive 
heart failure [138]. Besides the general health benefits associated with regular 
exercise, many diabetic patients do not regularly exercise due to symptoms 
associated with DN. Numerous primary therapies have been attempted in DN, 
with variable results. Management primarily relies on the pharmacological 
treatment of symptoms associated with DN (e.g. neuropathic pain) [139]. 
Currently, there is no form of therapy that has been identified to provide 
unequivocal, safe, and effective stabilization or reversal of the DN [51]. However, 
our results support the idea that long-term exercise can be used to complement 
current treatment strategies aimed at decreasing neuropathic pain in patients 
with DN, which may aid in decreasing the dependency of medication. 
 
3.5.4 Conclusion 
Results obtained from our study, demonstrates the influence voluntary 
exercise has on attenuating the severity of behavioral hypersensitivity to 
mechanical stimuli associated with DN in female rats. The significance of this 
research has given insight to possible mechanism by which exercise has an 
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effect on reducing mechanical allodynia in diabetic females. The present study 
has set the foundation for future studies examining the production and 
transportation of GDNF along with the therapeutic effects it may have. The 
mechanism by which exercise attenuates DN is poorly understood and more 






















Effect of voluntary exercise on mechanical allodynia and GDNF production 




The mechanisms that lead to painful symptoms associated with DN 
remain elusive. Growth factor deficiency (e.g. GDNF) is one of the main 
aetiologies of DN, which may be due to disturbances in axonal transport. Studies 
have shown that exercise can increase GDNF and axonal transport of proteins, 
however, the ability of exercise to increase transport of GDNF to areas in need of 
trophic support, which may reduce behavioral sensitivity associated with DN, has 
yet to be explored. Therefore, the purpose of this study is to determine how 
diabetes affects GDNF production and transport and whether voluntary exercise 
has any influence in order to attenuate or delay mechanical sensitivity associated 
with DN. Inbred A/J mice were randomized into a sedentary (Sed-C) and 
exercised (Ex-C) non-diabetic control group or a sedentary (Sed-D) and 
exercised (Ex-D) diabetic group. The diabetic groups received streptozotocin 
(STZ)-injections to induce diabetes. The exercised mice were housed in standard 
cages with access to voluntary running wheels. To quantify DN, mechanical 
allodynia (assessed via von Frey filaments) was measured prior to STZ-injections 
and once a week for 6 weeks following injections. GDNF protein levels and 
mRNA expression were analyzed in the lumbar region of the spinal cord, dorsal 
root ganglion, sciatic nerve, and skeletal muscle. GDNF axonal transport was 
assessed in the sciatic nerve using the double ligation technique. At diabetes 
duration of 6 weeks, the diabetic animals exercised about 3 Km/day. After 6 
weeks, diabetes significantly increased mechanical allodynia, however, 6 weeks 
of voluntary exercise alleviated mechanical allodynia in the Ex-D group 
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compared to the Sed-D group (2.8g vs. 1.6g, respectively). Six weeks of diabetes 
significantly decreased GDNF levels in the spinal cord, whereas voluntary 
exercise increase GDNF protein levels in the spinal cord and sciatic nerve along 
with mRNA expression in skeletal muscle compared to it sedentary counterpart. 
Two weeks of voluntary exercise increased GDNF protein levels in the sciatic 
nerve, which is when mechanical thresholds in the Ex-D group returned to 
baseline levels. Voluntary exercise increased axonal transport in the exercised 
diabetic group, particularly in an anterograde direction. Measurements of the 
degree of exercise (total distance) significantly correlated with the amount of 
GDNF accumulated in the proximal segment of the sciatic nerve, suggesting that 
the amount of exercise may regulate levels of GDNF production and transport 
from motoneurons. To determine the potential therapeutic actions GDNF may 
have, intrathecal injections of recombinant GDNF were administered for two 
weeks. Similar to the 6 week study, intrathecal injections of recombinant GDNF 
ameliorated mechanical sensitivity associated with DN. Voluntary exercise 
decreased mechanical allodynia and this reduction may be due to an increase in 
GDNF and axonal transport of this neurotrophic factor to areas in need of trophic 
support. Thus this study supports the use of voluntary exercise to complement 




Under normal conditions, nerve fibers maintenance in the periphery is 
balanced between nerve degeneration and regeneration; however diabetes 
impairs the ability of the diabetic nerve to regenerate in response to the 
degenerative process. Therefore, structural changes in the peripheral nerve such 
as axonal atrophy, demyelination, loss of nerve fibers, and the blunted 
regeneration of the nerve fibers may occur, ultimately leading to DN [52-54]. The 
decreased nerve regenerative capacity in diabetes has been associated with 
impaired neurotrophic support, which may reflect reductions in the availability of 
neurotrophic factors. It is believed that neurotrophic factor deficiency (e.g. GDNF) 
in diabetes may be due to disturbances in axonal transport, which is critical for 
maintaining normal metabolism, physiological activity, and structural integrity of 
the nerve [53, 91]. 
 
GDNF is a potent trophic factor that influences the development, survival, 
and maintenance of neurons in the central and peripheral nervous systems [54]. 
Recently, it has been shown that GDNF production is decreased in peripheral 
tissues of diabetic rats [54]. Therefore, the availability of GDNF through axonal 
transport for the survival of motor and sensory neurons is diminished. Studies 
have revealed that GDNF can be transported both anterogradely [95, 96] and 
retrogradely [97] within neurons. Several studies have shown that diabetes 
reduces axonal transport of neurotrophins (BDNF, NGF, and NT-3) [98-101], 
However GDNF axonal transport in diabetic animals has yet to be explored. 
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Earlier studies have shown that exercise can increase axonal transport of 
enzymes and proteins up to 20% and 50%, respectively, which can occur in both 
intact and deafferented nerves [91, 102-104]. Exercise-induced increases in 
axonal transport are due to increases in transport velocity in the neuron. It is 
believed that exercise increases neuronal activity leading to changes in the nerve 
terminal, therefore, axonal transport of proteins is increased in order to 
compensate for the effects exercise has on the distal parts of the neurons. As a 
result, the neuron is allowed to repair itself in order to return to normal nerve 
function [91]. 
 
The diabetic nerve is unable to maintain the normal 
degeneration/regeneration process, which leads to positive (parethesia as 
described as prickling, tingling, “pins and needles”, burning, crawling, itching, 
abnormal sensation to temperature, and pain) or negative (numbness, injury 
insensitivity) sensory symptoms. Exercise studies have alluded to that trained 
neurons are more responsive to alterations to their immediate neuronal 
environment. Therefore, experiments were performed to determine whether 
diabetic mice with mechanical allodynia display alterations in GDNF production 
and/or disruptions in and axonal transport, and whether voluntary exercise has 
any influence on these outcomes. Our results suggest that exercise can exert 
beneficial actions on painful DN, and these actions may be mediated by 






Ninety-seven male A/J mice (8 week old) were purchased from Jackson 
Laboratories.  Mice were housed in the animal facilities at the University of 
Kansas Medical Center (KUMC) where they were exposed to a 12 hour light/dark 
cycle and were given food and water ad libitum. All animal use protocols were 
approved by the Institutional Animal Care and Use Committee of the KUMC. 
 
4.3.1.1 6 week study 
Thirty-two mice were involved in a 6 week study. Mice were randomized 
into one of 4 groups: 1) sedentary non-diabetic control (Sed-C [n=7]), 2) 
exercised non-diabetic control (Ex-C [n=7]), 3) sedentary diabetic (Sed-D [n=11]), 
and 4) exercised diabetic (Ex-D [n=7]). Following randomization, all mice in the 
diabetic groups received two intraperitoneal (i.p.) injections of STZ (freshly 
dissolved in 10mM sodium citrate, pH 4.5, with 0.9% NaCl, [Sigma, St. Louis, 
MO]) on consecutive days (85 [day 1] and 65 [day 2] mg/kg body weight) to 
induce diabetes, where as the control animals were injected with 0.4 ml of 
sodium citrate buffer, pH 4.5. Mice were fasted 3 hours before and 3 hours after 
each injection. After injections, the exercised mice were housed in cages with 
access to voluntary running wheels while the sedentary groups were housed in 
cages without wheels. Weight and glucose levels were monitored weekly. 
Behavioral sensitivity to mechanical allodynia (assessed via von Frey filaments) 
was measured prior to injections and once a week for 6 weeks. All behavioral 
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assessments were performed on the plantar surface of the left hind paw. After 
the end of the 6 week experiment, mice were over-anesthetized with Avertin. 
Protein and mRNA analysis of the lumbar region of the spinal cord, dorsal root 
ganglia, sciatic nerve, and skeletal muscle (gastrocnemius) were conducted 
following the 6 week study. 
 
4.3.1.2 GDNF intrathecal injection study 
Thirty-five mice participated in a 2 week study. Mice were randomized into 
one of 5 groups (7 mice per group): 1) sedentary non-diabetic control (Sed-C), 2) 
exercised non-diabetic control (Ex-C), 3) sedentary diabetic (Sed-D), and 4) 
exercised diabetic (Ex-D), and 5) sedentary diabetic with GDNF intrathecal 
injections (Sed-DWG). Induction of diabetes, animal housing, and behavioral 
testing were the same to that of the 6 week study. After induction of diabetes, 
mice in the Sed-DWG group received daily intrathecal injections of human 
recombinant GDNF for 2 weeks. After the end of the 2 week experiment, mice 
were sacrificed and GDNF protein levels were analyzed in the lumbar region of 
the spinal cord and sciatic nerve. 
 
4.3.1.3 Double ligation study 
Twenty-nine mice were randomly assigned to 5 groups. Groups’ consisted 
of a sedentary (Sed-C [n=7]) and exercised (Ex-C [n=7]) non-diabetic control 
group, a sedentary (Sed-D [n=7]) and exercised (Ex-D [n=7]) diabetic group, and 
a sedentary non-diabetic sham group (Sed-Sham [n=1]). Induction of diabetes 
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and animal housing were the same to that of the 6 week study. Six weeks after 
injections, double ligation of the sciatic nerve was used to measure GDNF 
transport. The double ligation technique was used to measure GDNF levels 
obtained in specific regions of sciatic nerve (distal, middle or in-between the 
ligation, and proximal). This technique was used for the following reasons: 1) it 
interrupts axonal flow, thus allowing us to visualize and quantify the transported 
substance; 2) it provides clear separation of proximal and distal segments of the 
ligated nerve, demonstrating retrograde and anterograde transport of substances 
by accumulation in these segments; 3) accumulation of some substances in the 
proximal segment of the ligated nerve fibers provides evidence for anterograde, 
whereas accumulation in the distal segment suggests retrograde transport; and 
4) the increase and accumulation of the same substance in the middle segment 
provides information about local synthesis of the substance [140]. 
 
4.3.2 Running methods 
Exercised mice were individually housed in their own cage containing an 
exercise wheel (Mini Mitter Co. Inc., a Respironics Company, Bend, OR), thus, 
all exercise was voluntary. Each wheel revolution was continuously recorded and 
summarized in 30 minute intervals with the Vital View Data Acquisition System 
(Mini Mitter Co. Inc.) throughout the duration of the study. Sedentary rats were 





4.3.3 Behavioral analysis: mechanical allodynia 
Mice primarily exercised from 6pm to 6am, to avoid acute exercise effects 
all behavioral assessments were done 4 hours after they ceased running. Mice 
were placed under a transparent plastic dome on an elevated wire grid. A 
standard set of Semmes-Weinstein von Frey hairs (Stoelting, Wood Dale, IL), 
which are a series of nylon monofilaments of increasing stiffness that apply 
defined levels of force (grams) as they are pressed to the point where they bend, 
were applied in sequence to the plantar surface of the left hind paw. Starting with 
the filament that possesses a buckling weight 0.15g, a positive response is 
recorded after lifting of the paw and the next lightest filament is used for the next 
measurement. Absence of a response after 5 seconds, the next filament of 
increasing weight was used. This procedure continued until four measurements 
were made after an initial change in the behavior or until five consecutive 
negative (given the score of 6g) or four positive (score of 0g) scores occur. All 
behavioral assessments were performed on the plantar surface of the left hind 
paw. Behavioral assessments were performed once a week for 2 or 6 weeks 
[141]. 
 
4.3.4 Induction of diabetes 
Following randomization, diabetes was induced by two intraperitoneal 
(i.p.) injections of STZ (freshly dissolved in 10mM sodium citrate, pH 4.5, with 
0.9% NaCl, [Sigma, St. Louis, MO]) on consecutive days (85 [day 1] and 65 [day 
2] mg/kg body weight), where as the control mice were injected with 0.4 ml of 
132 
 
sodium citrate buffer, pH 4.5. Mice were fasted 3 hours before and 3 hours after 
each injection. Mice weight and blood glucose (using glucose diagnostic 
reagents; Sigma) were measured 1 week post STZ-injection and once a week 
throughout the study. Mice were included in the diabetic group if their blood 
glucose levels were >16.0 mmol/L at every measure. 
 
4.3.5 Intrathecal injections 
After induction of diabetes, mice were injected intrathecally once per day 
with human recombinant GDNF. GDNF was dissolved in aritificial cerebrospinal 
fluid at a concentration of 20nM. Intrathecal injections (50 μl, 1μg GDNF) were 
performed according to Christianson et al. (2003) between the L6 and S1 
vertebrae with a 27-guage needle. Intrathecal delivery of GDNF was used to 
provide the best opportunity to deliver GDNF to the spinal cord and to avoid 
problems associated with poor retrograde transport of GDNF from the periphery. 
 
4.3.6 Double ligation technique 
Under Avertin anesthesia, the skin on the lateral surface of the left thigh 
was incised revealing the muscle. Using forceps, a section was made directly 
through the bicep femoris muscle exposing the sciatic nerve. Ligations consisting 
of two 4.0 silk ligatures were tied tightly around the sciatic nerve about 3mm 
apart at the mid-thigh. Muscle and skin were closed using 4.0 silk sutures. Sham 
surgery procedures were performed as above, however it only involved exposure 
of the sciatic nerve without any ligations. The double ligatures were applied for 
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18-20hrs, as suggested by several studies [95, 96, 100, 140]. The mice were 
over-anesthetized using Avertin, and the left sciatic nerve was exposed and 
intermediately frozen with tissue tech and placed at -80˚C until further analysis. 
 
4.3.7 Protein analysis 
GDNF protein levels were examined in the lumbar region of the spinal 
cord, DRG, sciatic nerve, and skeletal muscle (gastrocnemius) using immunoblot 
analysis. The harvested tissues of the mice were collected during dissection and 
immediately frozen in liquid nitrogen, to preserve protein integrity, and stored at -
80˚C until use. Tissues were homogenized using lysis buffer containing 137mM 
NaCl, 20mM Tris-HCl, pH 8.0, 1% nonyl phenoxylpolyethoxylethanol (NP-40), 
10% glycerol, 1mM phenylmethanesulfonylfluoride (PMSF), 10μg/ml aprotinin, 
1μg/ml leupeptin, and 0.5mM sodium vanadate. Tissue weight to buffer volume 
ratio was kept at 1:20 (e.g. 400μl buffer per 20mg tissue) for the spinal cord and 
skeletal muscle and at 1:50 for the DRG and sciatic nerve. In the lysis buffer, 
tissues were homogenized using a glass Teflon homogenizer, and then 
centrifuged at +4˚C, at 16,000g for 15 minutes. The supernatant was collected 
and total protein concentration was measured using BioRad protein assay 
reagent (BioRad Laboratories, Hercules, CA) in a 96 wellplate format, and  
analyzed with the microplate reader MRXII (Dynex Technologies, Chantilly, VA) 
using bovine serum albumin as standard. Polyacrylamide gel electrophoresis in 
the presence of sodium dodecyl sulfate was used to separate proteins in the 
supernatants. Fourteen percent polyacrylamide gels with 15 wells for protein 
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loading were poured using electrophoresis grade reagents. Twenty (spinal cord), 
50 (DRG and sciatic nerve), and 100 (skeletal muscle) micrograms of total 
protein per sample was loaded per well of a gel, and proteins were separated 
under ~150-200 V current at constant voltage (30 mA). The separated proteins 
were transferred to a polyvinylidene fluoride (PVDF) membrane over night using 
sandwich tank transfer apparatus (Bio-Rad Laboratories). Membranes were 
blocked using a blocking buffer consisting of fresh 3% non-fat dry milk (BioRad 
Laboratories) suspended in phosphate buffered saline (PBS) with 0.1% Tween 
20 (PBS-T) for 1 hour. Membranes were then incubated with primary antibody 
(GDNF rabbit-polyclonal [Santa Cruz Biotechnology, Santa Cruz, CA, catalog # 
sc-328; dilution 1:2,000]) diluted in the blocking buffer, for 1 hour. The membrane 
was then washed 3 times with PBS-T for 10 minutes each. The membrane was 
then incubated for 30 minutes with the secondary antibody (goat anti-rabbit 
[Santa Cruz Biotechnology, catalog # sc-2004; dilution 1:2,000]) in the blocking 
buffer and then washed 3 times in PBS-T for 10 minutes.  All membrane 
incubations and washes were done at room temperature on a shaker. Detection 
was achieved using enhanced chemiluminescent reagent (ECL; 
SuperSignalWestPico Chemiluminescent Substrate, catalog # 34080, Pierce, 
Rockford, IL]) according to manufacturer’s recommendations, and exposure of 
membranes to X-ray film. The relative levels of protein were estimated by 
measuring mean pixel intensity of protein bands using Adobe Photoshop. Before 
the blocking step, all membranes were stained with Ponceau S solution to verify 
even loading, integrity of the extracted proteins and proper transfer [124]. If 
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uneven loading of protein occurred, a single band on the Ponceau stained 
membrane was used for normalization. GDNF was detected as a single band 
migrating at a molecular weight of 36 kilodaltons (kDa). The specificity of the 
band was confirmed using a GDNF blocking peptide (Santa Cruz Biotechnology, 
catalog #sc-328P). 
 
4.3.8 mRNA analysis 
The expression of GDNF was examined in the lumbar region of the spinal 
cord, DRG neuron, and skeletal muscle (gastrocnemius) using real time reverse 
transcription-polymerase chain reaction (RT-PCR) technique.  At week 6 all mice 
were over-anesthetized using a single injection of Avertin, and tissues were 
dissected. Tissues were homogenized in Trizol reagent (Invitrogen, Carlsbad, 
CA) using a glass Teflon homogenizer. With use of Rneasy Mini Kit (Qiagen 
Sciences, Maryland, USA) total RNA will be extracted according to the 
manufacturer’s instructions. RT reaction was performed using iScript cDNA 
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) in order to convert mRNA to 
cDNA. The resulting cDNA was subjected to PCR amplification using Taqman 
Gene Expression Assay (Applied Biosystem, Foster City, CA, 
#Mm00599849_m1) as per manufacturer’s protocol, and MyiQ Single Color Real 
Time PCR Detection System machine (Bio-Rad Laboratories). The size of the 
PCR products was checked by 2% agarose gel-electrophoresis and staining with 
ethidium bromide. GDNF gene expression was determined relative to the 




Following nerve ligation, GDNF protein levels were assessed in the sciatic 
nerve of mice. The double ligated nerve was sectioned on a cryostat at 7μm and 
placed on microscope slides. Slides were encircled with a hydrophobic barrier 
using a Pap Pen (Research Products International, Mt. Prospect, IL), which were 
then treated with a blocking solution (0.5% porcine gelatin, 1.5% normal donkey 
serum, 0.5% Triton-X in Superblock Buffer [Pierce, Rockford, IL]) for 1 hour at 
room temperature. Sections were then incubated overnight at +4˚C with primary 
antibody (GDNF rabbit-polyclonal [Santa Cruz Biotechnology, #sc-328; diluted 
1:100]) that was diluted in blocking solution. Sections were washed 2 x 10 
minutes with PBS-T followed by incubation for 1 hour with fluorochrome-
conjugated secondary antibody (donkey anti-rabbit Alexa 555; 1:2,000; Molecular 
Probes, Eugene, OR) diluted in PBS-T and Superblock (1:1 ratio). Following 
incubation, sections were washed in PBS for 2 x 10 minutes. After washing, 
slides were cover slipped and stored at +4˚C until viewing [142]. The relative 
levels of GDNF were detected by measuring threshold levels in the sciatic nerve 
using ImageJ. Minimum and maximum threshold levels were set at 20 and 50 
pixels, respectively. Each segment (distal, middle, and proximal) of the sciatic 
nerve was photographed using a Nikon Eclipse E800 fluorescent microscope at 
20x magnification. Using ImageJ percent area of GDNF coverage was obtained 
by measuring area accumulated with GDNF divided total area of the segment of 




4.3.10 Data analysis 
Data analyses were conducted for each variable. One-way analysis of 
variance (ANOVA) with repeated measures was applied for between groups 
comparisons for daily distance exercised, blood glucose, body weight, and 
mechanical allodynia. When appropriate, Post hoc analyses were conducted with 
a least significant difference (L-S-D) method. Independent samples t-test was 
used to analyze GDNF protein levels and mRNA expression. The Pfaffl method 
was used to calculate the relative expression ratio (fold differences) of GDNF 
expression compared to the Sed-C group [143]. Pearson Product Correlation 
was used to determine the relationship between daily exercise distance and 
changes in behavioral sensitivity, relationship between total distance exercised 
and GDNF levels at week 2 and 6, and the relationship between total distance 
exercised and GDNF axonal transport at week 6. Statistical significance was set 
at p≤0.05. Data are represented as mean ± standard error of the mean (SEM). 
 
4.4 Results 
4.4.1 6 week study 
4.4.1.1 Animal characteristics 
Blood glucose for the non-diabetic groups did not change over the 6 week 
study (Figure 4.1). After STZ-injections the diabetic groups had marked increase 
in blood glucose compared to their respective controls. During the first 5 weeks 
voluntary exercise did not have an effect on blood glucose in the diabetic 
animals. However, there was a significant difference between the diabetic 
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Figure 4.1 Blood glucose levels in mice throughout the 6 week study. STZ-
injections markedly increase in blood glucose of the diabetic groups compared to 
their respective controls. Voluntary exercise significantly improved blood glucose 
levels of the exercised diabetic group compared to the sedentary diabetic group 
at week 6 (19.5±0.8 vs. 16.3±0.7 mmol/L, respectively). *=Sed-C vs. Sed-D, 




Figure 4.1 Blood glucose levels in mice throughout the 6 week study. 
  





























sedentary and diabetic exercise group at week 6 (19.5±0.8 vs. 16.3±0.7 mmol/L, 
respectively). 
 
Over the 6 week study the Sed-C group exhibited a 13.5% increase in 
body weight (Figure 4.2). Six weeks of voluntary exercise prevented any changes 
in body weight in the Ex-C group (0.9%), which was significantly less than their 
sedentary counterpart. Both diabetic groups exhibited significant reductions in 
body weight compared to their respective controls. The diabetic sedentary and 
exercised groups displayed a 13.6% and 16.7% reduction in body weight over 
the 6 week experiment, respectively, however voluntary exercise further reduces 
body weight among the diabetic mice. 
 
4.4.1.2 Exercise data 
Mice were given unlimited access to voluntary running wheels for 6 
weeks. At week 6 the Ex-C and Ex-D mice exercised on average 3.6±0.4 and 
3.5±0.4 km/day, respectively (Figure 4.3). There were no significant differences 
in distance ran between the exercised non-diabetic and diabetic groups 
throughout the 6 week training period. 
 
4.4.1.3 Behavioral assessments: mechanical allodynia 
One week after STZ-injections, both diabetic groups exhibited an increase 
in mechanical allodynia; suggesting this inbred mouse strain develops a painful 
neuropathy. At week 6, the sedentary diabetic group displayed a significantly 
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Figure 4.2 Body weight of the mice throughout the 6 week study. The Sed-C and 
Ex-C group exhibited a 13.5% and 0.9% increase in body weight. The Sed-D and 
Ex-D groups displayed a 13.6% and 16.7% reduction in body weight over the 6 
week experiment, respectively, which was significantly less than their respective 
control. *=Sed-C vs. Sed-D, †=Ex-C vs. Ex-D, ‡=Sed-D vs. Ex-D, and §=Sed-C 




Figure 4.2 Body weight of the mice throughout the 6 week study. 
  
































Figure 4.3 Average daily exercise distance throughout the 6-wk study. During 




Figure 4.3 Average daily exercise distance throughout the 6-wk study. 
  


















higher mechanical allodynia compared to sedentary non-diabetic control group 
(1.6±0.3 vs. 2.8±0.5 grams, respectively). However, 6 weeks of voluntary 
exercise attenuated mechanical allodynia in the diabetic exercised group 
compared to the sedentary diabetic group (3.3±0.3 vs. 1.6±0.3 grams, 
respectively). There were no changes in behavioral sensitivity among the non-
diabetic groups (Figure 4.4). There were no correlations with daily exercised 
distance and changes in mechanical allodynia or GDNF proteins levels in the 
spinal cord, DRG, sciatic nerve, and skeletal muscle. 
 
4.4.1.4 GDNF protein analysis 
Protein analysis was used to determine the effects voluntary exercise has 
on GDNF protein levels in the lumbar region of the spinal cord tissue (Figure 
4.5), DRG (Figure 4.6), sciatic nerve (Figure 4.7), and skeletal muscle 
(gastrocnemius [Figure 4.8]). Six weeks of diabetes decreased GDNF protein 
levels in spinal cord of the sedentary diabetic group by 4.7-fold compared to 
sedentary non-diabetic control group. However, voluntary exercise significantly 
increased GDNF levels in the exercised diabetic group by 3.1-fold compared to 
the sedentary diabetic group. Exercise did not alter GDNF protein levels in the 
non-diabetic group and there were no significant differences between either 
exercised groups. In the DRG, the sedentary diabetic group exhibited a marked 
1.9-fold increase of GDNF compared to the sedentary non-diabetic control group; 
however voluntary exercise had no effect on GDNF levels among the diabetic 
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Figure 4.4 Mechanical allodynia assessed using a von Frey monofilament test 6 
weeks post STZ-injection. Diabetes significantly increased mechanical allodynia 
compared to it sedentary counterpart (1.6±0.3 vs. 2.8±0.5 grams, respectively). 
At week 6 exercise favorably increased pain thresholds in diabetic mice 
compared to their sedentary counterpart (3.3±0.3 vs. 1.6±0.3 grams, 




Figure 4.4 Mechanical allodynia assessed using a von Frey monofilament test 6 
weeks post STZ-injection. 
  






























Figure 4.5 Immunoblot analysis of GDNF levels in the lumbar region of the spinal 
cord 6 weeks post STZ-injection. A.) Sed-C versus Sed-D. B.) Sed-C versus Ex-
C. C.) Sed-D versus Ex-D. D.) Ex-C versus Ex-D; Upper panel shows 
representative immunoblot; Lower panel shows histogram analysis of the 
immunoblot. Diabetes significantly decreased GDNF, whereas, the Ex-D group 
demonstrated an increase in GDNF levels compared to Sed-D after 6 weeks of 
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Figure 4.6 Immunoblot analyses of GDNF levels in the DRG 6 weeks post STZ-
injection. A.) Sed-C versus Sed-D. B.) Sed-C versus Ex-C. C.) Sed-D versus Ex-
D. D.) Ex-C versus Ex-D; Upper panel shows representative immunoblot; Lower 
panel shows histogram analysis of the immunoblot. Diabetes significantly 
increased GDNF levels. Voluntary exercise increased GDNF levels among the 
control group, however, exercise did not alter GDNF levels among the diabetic 
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Figure 4.7 Immunoblot analysis of GDNF levels in the sciatic nerve 6 weeks post 
STZ-injection.  A.) Sed-C versus Sed-D. B.) Sed-C versus Ex-C. C.) Sed-D 
versus Ex-D. D.) Ex-C versus Ex-D; Upper panel shows representative 
immunoblot; Lower panel shows histogram analysis of the immunoblot. Diabetes 
had no effect of GDNF levels; however, voluntary exercise significantly increased 
GDNF levels among both exercised groups compared to their sedentary 
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Figure 4.8 Immunoblot analysis of GDNF levels in the gastrocnemius skeletal 
muscle 6 weeks post STZ-injection. A.) Sed-C versus Sed-D. B.) Sed-C versus 
Ex-C. C.) Sed-D versus Ex-D. D.) Ex-C versus Ex-D; Upper panel shows 
representative immunoblot; lower panel shows histogram analysis of the 
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group. Six weeks of voluntary exercise increased GDNF levels in the exercised 
non-diabetic control group by 1.7-fold compared to the sedentary non-diabetic 
control and exercised diabetic group. Diabetes did not alter GDNF in the sciatic 
nerve among the sedentary groups. However, voluntary exercise robustly 
increased GDNF levels in the exercised non-diabetic and diabetic groups by 2.2 
and 3.5-fold compared to their sedentary counterparts, respectively. The 
exercised diabetic group also showed a 1.9-fold increase in GDNF compared to 
the exercised non-diabetic control group. Diabetes and exercise did not alter 
GDNF protein levels in skeletal muscle. There were no correlations with total 
distance exercised and GDNF proteins levels in the spinal cord, DRG, sciatic 
nerve, and skeletal muscle. 
 
4.4.1.5 GDNF mRNA analysis 
RT-PCR was used to determine the effects voluntary exercise has on 
GDNF mRNA expression in the lumbar region of the spinal cord tissue (Figure 
4.9), DRG (Figure 4.10), and skeletal muscle (gastrocnemius [Figure 4.11]). RT-
PCR was not assessed in the sciatic nerve due to the inability to obtain enough 
RNA to perform the assay. Voluntary exercise favorably increased GDNF mRNA 
expression in gastrocnemius muscles of diabetic mice. The Ex-D group exhibited 
a significant 4.3-fold increase in GDNF expression compared to the Sed-D group. 
Changes in GDNF expression were not detected in the gastrocnemius muscle 
among the non-diabetic control groups. Changes in GDNF expression due to 
diabetes and exercise in the spinal cord or DRG were not detected.   
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Figure 4.9 mRNA analysis of GDNF levels in the lumbar region of the spinal cord 
6 weeks post STZ-injection. A.) Change in cycle threshold (delta [Δ] CT) and B.) 
Fold change in GDNF expression compared to the Sed-C group. Changes in 




Figure 4.9 mRNA analysis of GDNF levels in the lumbar region of the spinal cord 
6 weeks post STZ-injection. 
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Figure 4.10 mRNA analysis of GDNF levels in the DRG 6 weeks post STZ-
injection. A.) Change in cycle threshold (delta [Δ] CT) and B.) Fold change in 
GDNF expression compared to the Sed-C group. Changes in GDNF expression 




Figure 4.10 mRNA analysis of GDNF levels in the DRG 6 weeks post STZ-
injection.
A.) 








































Figure 4.11 mRNA analysis of GDNF levels in the gastrocnemius skeletal 
muscle 6 weeks post STZ-injection. A.) Change in cycle threshold (delta [Δ] CT) 
and B.) Fold change in GDNF expression compared to the Sed-C group. 
Voluntary exercise significantly increased GDNF expression of the exercised 




Figure 4.11 mRNA analysis of GDNF levels in the gastrocnemius skeletal muscle 






































































4.4.2 GDNF intrathecal injection study 
4.4.2.1 Animal characteristics 
After STZ-injections, all diabetic groups exhibited a marked increase in 
plasma glucose compared to their respective controls, which persisted 
throughout the study (Figure 4.12). There were no significant differences in blood 
glucose levels between the Sed-D group and Sed-DWG (23.9 vs. 19.8 mmol/L, 
respectively). Similar to the 6 week study, 2 weeks of voluntary exercise did not 
affect blood glucose levels compared to its sedentary diabetic counterpart (24.0 
vs. 23.9 mmol/L, respectively). Blood glucose for the sedentary non-diabetic 
control group did not change over the 2 week experiment and exercise had no 
effect on plasma glucose levels in the non-diabetic group (4.6 vs. 4.8 mmol/L, 
respectively). 
 
Two weeks after STZ-injections the Sed-D, Sed-DWG, and Ex-D groups 
exhibited a 19.3%, 20.0%, and 23.8% reduction in body weight, respectively 
(Figure 4.13). At week 2, the Sed-C group showed a 3.1% increase in body 
weight, which was significant greater compared to their sedentary counterparts. 
Two weeks of voluntary exercise maintained basal body weight levels in the Ex-C 







Figure 4.12 Blood glucose levels in mice throughout the 2 week study. All 
diabetic groups exhibited a marked increase in plasma glucose compared to their 





























Figure 4.13 Body weight of mice throughout the 2 week study. At week 2, the 
Sed-C group showed a 3.1% increase in body weight, whereas, the Sed-D, Sed-
DWG, and Ex-D groups exhibited a 19.3%, 20.0%, and 23.8% reduction in body 






Figure 4.13 Body weight of mice throughout the 2 week study. 

























4.4.2.2 Exercise data 
Similar to the 6 week study all mice were given unlimited access to 
voluntary running wheels for 2 weeks. At week 2 the Ex-C and Ex-D mice 
exercised on average 1.8±0.6 and 1.7±0.6 km/day, respectively (Figure 4.14). 
There were no significant differences in distance exercised between the non-
diabetic and diabetic exercise groups throughout the 2 week training period. 
 
4.4.2.3 Behavioral assessments: mechanical allodynia 
Similar to the 6 week study, diabetes increased mechanical allodynia by 
week 1 in the sedentary and exercised groups (Figure 4.15). Two weeks of 
voluntary exercise attenuated mechanical allodynia in the diabetic group 
compared to it sedentary counterpart (2.8±0.5 vs. 1.6±0.3 grams, respectively). 
Similar to voluntary exercise, 2 weeks of intrathecal injections of GDNF 
ameliorated changes in mechanical allodynia among the diabetic sedentary 
group (Sed-DWG), thus suggesting a potential therapeutic effect GDNF may 
exhibit. Again exercise did not alter mechanical allodynia in the non-diabetic 
control groups and there were no differences between exercised groups. Similar 
to the 6 week study there were no correlations with daily exercised distance and 
changes in mechanical allodynia. 
 
4.4.2.4 GDNF protein analysis 
The 6 week study showed increases in protein levels of GDNF in the 
lumbar region of the spinal cord and sciatic nerve. Therefore, immunoblot  
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Figure 4.14 Average daily exercised distance throughout the 2 week study. 
























Figure 4.15 Mechanical allodynia assessed using a von Frey monofilament test 
2 weeks post STZ-injection. 2 weeks of GDNF administration attenuated the 
development of behavioral sensitivity associated with DN. *=Sed-C vs. Sed-D, 
†=Ex-C vs. Ex-D, ‡=Sed-D vs. Ex-D, and §Sed-D vs. Sed-DWG. p<0.05 
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Figure 4.15 Mechanical allodynia assessed using a von Frey monofilament test 2 






























analysis was used to determine whether the reduction in mechanical allodynia, 
which is seen after 2 weeks of voluntary exercise were due to an increase in 
GDNF in the lumbar region of the spinal cord and sciatic nerve. Two weeks of 
diabetes and voluntary exercise did not alter GDNF protein levels in spinal cord 
(Figure 4.16). However, there is a trend showing an increase in GDNF protein 
levels in the exercised diabetic group compared to the diabetic sedentary group. 
GDNF protein levels were 1.7-fold higher in the Sed-C group compared to the 
Ex-C group. There were no significant differences between either exercised 
groups. In the sciatic nerve there were no differences in GDNF protein levels 
when comparing the sedentary (Sed-C vs. Sed-D), control (Sed-C vs. Ex-C), and 
exercised groups (Ex-C vs. Ex-D). However, exercise did significantly increased 
GDNF proteins levels in the sciatic nerve of the exercised diabetic group 
compare to its sedentary counterpart (Figure 4.17). Therefore, the attenuation of 
mechanical allodynia exhibited by the diabetic exercised group at day 14 may be 
due to increases in GDNF protein levels in the sciatic nerve. Total distance 
exercised at week 2 did not correlate with GDNF protein levels in the spinal cord 
or sciatic nerve. 
 
4.4.3 Double ligation study 
4.4.3.1 Animal characteristics 
Six weeks after STZ-injection the diabetic groups had a significantly higher 
blood glucose levels compared to their respective controls (Figure 4.18). There 
were no differences between diabetic groups. At week 6, voluntary exercise did   
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Figure 4.16 Immunoblot analysis of GDNF levels in the lumbar region of the 
spinal cord 2 weeks post STZ-injection. A.) Sed-C versus Sed-D. B.) Sed-C 
versus Ex-C. C.) Sed-D versus Ex-D. D.) Ex-C versus Ex-D; Upper panel shows 
representative immunoblot; lower panel shows histogram analysis of the 
immunoblot. 2 weeks of diabetes and voluntary exercise had no effect on GDNF 




Figure 4.16 Immunoblot analysis of GDNF levels in the lumbar region of the 
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Figure 4.17 Immunoblot analysis of GDNF levels in the sciatic nerve 2 weeks 
post STZ-injection. A.) Sed-C versus Sed-D. B.) Sed-C versus Ex-C. C.) Sed-D 
versus Ex-D. D.) Ex-C versus Ex-D; Upper panel shows representative 
immunoblot; lower panel shows histogram analysis of the immunoblot. Voluntary 
exercise significantly increased GDNF levels in the exercised diabetic group 
compared to the sedentary diabetic group. * p<0.05 
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Figure 4.18 Blood glucose levels in the mice at the end of 6 weeks in the double 
ligation study. STZ-injection markedly increased blood glucose levels among the 
diabetic groups compared to their respective controls. Voluntary exercise had no 




Figure 4.18 Blood glucose levels in the mice at the end of 6 weeks in the double 
ligation study. 
 

















not alter glucose levels among the control or diabetic groups (Ex-C [4.9 mmol/L] 
vs. Sed-C [5.5 mmol/L] and Sed-D [21.2 mmol/L] vs. Ex-D [20.3 mmol/L]). 
 
Similar to the prior 6 week study the diabetes significantly decreased the 
body weight compared to their respective control group (Figure 4.19). The Ex-D 
group exhibited greater weight losses compared to the Sed-D group (17.2g vs. 
18.4g), although it was not significant. Among the control groups, the Sed-C 
group exhibited a 9% increase in body weight, whereas as voluntary exercise 
prevented an increase in body weight (21.3g [at day 0] to 21.9g [at day 43]). 
 
4.4.3.2 Exercise data 
There were no significant differences in daily exercised distance between 
the non-diabetic and diabetic exercise groups throughout the first 5 weeks of the 
training period. However, at week 6 the Ex-C exercised significantly more than 
the Ex-D group (5.6±0.9 vs. 2.8±1.1 km/day, respectively, [Figure 4.20]). 
 
4.4.3.3 GDNF transportation 
GDNF axonal transport was assessed in the sciatic nerve using the 
double ligation technique. With this technique we are able to assess whether 
GDNF is being transported anterogradely (accumulation on proximal segment of 
nerve), retrogradely (accumulation on distal segment of nerve, or produced 
locally (accumulation in the middle segment of nerve). GDNF is present in an 
intact sciatic nerve (Figure 4.21). Table 1 lists areas that GDNF accumulated in  
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Figure 4.19 Body weight of the mice at the end of 6 weeks in the double ligation 
study. 6 weeks of diabetes duration significantly decreased the body weight of 




Figure 4.19 Body weight of the mice at the end of 6 weeks in the double ligation 
study. 















Figure 4.20 Average daily exercise distance throughout the 6 week double 
ligation study. During week 6 the Ex-C and Ex-D groups exercised 5.6±0.9 and 
2.8±1.1 km/day, respectively. * p<0.05 
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Figure 4.20 Average daily exercise distance throughout the 6 week double 
ligation study. 




















Figure 4.21 Immunohistochemical localization of GDNF in the distal, middle, and 
proximal areas of the sciatic nerve; sedentary non-diabetic control. A.) no surgery 
and B.) sham surgery. GDNF is detectable in the axons of the sciatic nerve. The 









Figure 4.21 Immunohistochemical localization of GDNF in the distal, middle, and 
roximal areas of the sciatic nerve. 
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Table 4.1 Accumulation of GDNF in an intact sciatic nerve, and in the distal, 
middle and proximal segments of the sciatic nerve after double ligation surgery. 
The sham surgery slightly increased GDNF levels in the sciatic nerve. All groups 
exhibited an increase in accumulation of GDNF in all three segments of the 
sciatic nerve. The Sed-C group exhibited a greater increase in the middle 
segment; however there was more GDNF accumulation in the proximal segment 
compared to the distal segment. The remainder groups had a greater 






Table 4.1 Accumulation of GDNF in an intact sciatic nerve, and in the distal, 




Percent Area (Mean ± SEM) 
 
 Distal Middle Proximal 
Sed-C 3.9 ± 0.8 11.0 ± 6.2 7.3 ± 3.2 
Ex-C 6.9 ± 1.9 9.3 ± 1.6 14.2 ± 2.9 
Sed-D 7.0 ± 2.8 9.5 ± 3.1 12.3 ± 3.5 








1.9 ± 0.3 
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the sciatic nerve. Although not significant the sham surgery slightly increased the 
amount of GDNF present in the sciatic nerve. After surgery, all groups exhibited 
an increase in accumulation of GDNF in all three segments of the sciatic nerve. 
The Sed-C group exhibited a greater increase in the middle segment; however 
there was more GDNF accumulation in the proximal segment compared to the 
distal segment. The remainder groups had a greater accumulation in the 
proximal segment compared to the middle and distal segments (Figure 4.22). 
The relationship between distance exercised and GDNF accumulation in the 
proximal segment was analyzed. In diabetic mice, total distance exercised 
significantly correlated with the amount of GDNF accumulated in the proximal 
segment of the double ligated sciatic nerve (r=.890, p=.018), illustrating that 
anterograde transport of GDNF increased with the amount of exercise the mice 
participated in (Figure 4.23). Exercise increased the amount of GDNF 
accumulation compared to their respective controls, suggesting that exercise has 
a favorable effect on increasing GDNF axonal transport. 
 
4.5 Discussion 
Painful DN is a prominent clinical problem with few treatment options. 
Here, we have tested the ability of voluntary exercise to improve pain indices in 
diabetic mice. Our results suggest that voluntary exercise significantly improves 
mechanical hypersensitivity in diabetic mice. Moreover, our studies suggest that 
these analgesic actions may be mediated by exercise-induced increases in 
neurotrophic factor levels. Voluntary exercise significantly increased GDNF   
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Figure 4.22 GDNF axonal transport in the sciatic nerve. Immunohistochemical 
localization of GDNF in the distal, middle, and proximal areas of the sciatic nerve 
of the double ligation study. A.) sedentary non-diabetic control, B.) exercised 
non-diabetic control, C.) sedentary diabetic, D.) exercised diabetic. Each 
segment of the sciatic nerve is a representative of the entire group. Bar = 100μm. 
All groups exhibited an increase in accumulation of GDNF in all three segments 
of the sciatic nerve. The Sed-C group exhibited a greater increase in the middle 
segment; however there was more GDNF accumulation in the proximal segment 
compared to the distal segment. The remainder groups had a greater 

















Figure 4.23 Plot of the levels of GDNF vs. total distance exercised in proximal 
side of the sciatic nerve after double ligation surgery. In diabetic mice, total 
distance exercised significantly correlated with the amount of GDNF accumulated 
in the proximal segment of the double ligated sciatic nerve (r=.890, p=.018), 
illustrating that anterograde transport of GDNF increased with the amount of 
exercise the mice participated in 
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Figure 4.23 Plot of the levels of GDNF vs. total distance exercised in proximal 




protein levels in the spinal cord and sciatic nerve, mRNA levels in skeletal 
muscle of exercised diabetic mice, and direct application of GDNF to the spinal 
cord and sensory neurons improved pain indices similar to exercise. These 
studies strongly suggest that exercise has beneficial actions on alleviating pain in 
diabetic patients and provide a potential mechanism by which exercise changes 
neurotrophic factor levels that are beneficial to neural pain circuitry. 
 
4.5.1 Mechanical allodynia in mice 
Sprague Dawley rats are well known as a model of diabetes-induced 
mechanical allodynia [116], but this is the first report of A/J inbred diabetic mice 
displaying a similar behavioral change. As early as one week after diabetes 
onset, sedentary diabetic mice exhibited a 31% increase in mechanical allodynia, 
which persisted throughout the duration of the studies. Other mouse strains have 
been reported to develop mechanical hypersensitivity, including leptin null mutant 
(ob/ob) mice that resemble Type 2 diabetes [144, 145]. However, other inbred 
mouse strains such as C57Bl/6 mice display mechanical insensitivity [84, 146]. 
Importantly, these differences in diabetes-induced behavioral sensitivity among 
different inbred strains may provide improved models to study the range of 
neuropathic changes present in humans with diabetic neuropathy. 
 
4.5.2 Exercise reduces mechanical allodynia 
Our results from the current study add to the view that exercised-induced 
alterations in pain sensitivity are sensitive to neurotrophic factor levels, which 
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was illustrated in our rat study. Experiments in the current study support this 
view, as 2 weeks of voluntary exercise increased GDNF levels in the sciatic 
nerve of diabetic mice, which is where the initial behavioral differences were 
seen, and intrathecal delivery of GDNF during the emergence of mechanical 
allodynia in diabetic mice restored mechanical sensitivity to normal levels. 
Collectively, these results strongly argue that GDNF may be a viable treatment 
for attenuating acute and chronic pain states associated with peripheral nerve 
damage. Although our results support the view that GDNF has potent therapeutic 
actions in painful diabetic neuropathy, our studies do not provide clear insight as 
to whether GDNF depletion in diabetes is involved in the initiation and 
maintenance of mechanical allodynia. 
 
4.5.3 Exercise and axonal transport 
An important issue related to the ability of exercise to increase GDNF 
levels is the site at which this occurs. GDNF is synthesized and secreted by a 
number of tissues [63] including various regions of the central nervous system 
[66, 67], peripheral nervous system [66], and peripheral tissues [68, 69]. To gain 
some perspective about the source(s) of GDNF in the spinal cord and sciatic 
nerve, we performed nerve ligation studies to determine if GDNF protein was 
transported retrogradely from the gastrocnemius muscle. Our results suggest 
that exercise-induced changes in GDNF increase both anterograde and 
retrograde levels of transported GDNF, with the greatest changes occurring in an 
anterograde direction. These findings are in agreement with previous studies that 
196 
 
report anterograde transport of GDNF in the sciatic nerve and hypoglossal nerve 
[95, 96] and retrograde transport in the sciatic nerve [97]. Western blots of GDNF 
protein in the dorsal or ventral spinal cord of exercised rats revealed that the 
greatest increases in GDNF protein occurred in the ventral horn, suggesting that 
motoneurons may play an important role in accumulating and/or synthesizing 
GDNF in response to exercise. We believe that this anterograde axonal transport 
is due to an increase accumulation of GDNF protein in the ventral horn, which 
was illustrated in our diabetic exercise rats. It is believed that the anterograde 
axonal transport of GDNF in the peripheral nerve may be released at the axon 
terminals in the skin and muscle, therefore possibly serving as a neuromodulator 
[95]. 
 
Based on these findings, it is plausible to suggest that GDNF may act as 
an important signaling molecule that is responsive to exercise and serves to 
modulate central neural signaling and peripheral tissue function. Exercised-
induced increases in GDNF occurred in skeletal, which may influence spinal 
circuitry via retrogradely transport and released within the spinal cord. Exercise 
then increases GDNF levels in neural tissues that are transported anterogradely 
to influence peripheral tissues. It is possible that these mechanisms represent 
endogenous systems that enable communication between sensory/motor 
neurons and peripheral tissues that respond to exercise. Finally, we have 
demonstrated in the current study that this potential mechanism may be 
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heightened in the disease setting of diabetes in which neurotrophic signaling may 
be compromised. 
 
4.5.4 Clinical implications 
Understanding the effects diabetes has on neurotrophic support and 
function in neurons is critical for understanding and alleviating secondary 
complications associated with painful DN. Currently, long-term glycemic control is 
the only treatment recommended to treat degenerative DN [113]. Recently, it has 
been shown that voluntary exercise enhances axonal regeneration of sensory 
neurons [128]. In diabetic animals, exercise prevents myelin damage, therefore 
protecting and attenuating electorphysiological deficits that occur in the setting of 
DN [62]. Our study demonstrated that voluntary exercise and recombinant GDNF 
can alleviate mechanical allodynia in diabetic mice. Exercise-induced changes in 
mechanical allodynia are believed to be due increasing GDNF levels and the 
availability of this trophic factor through axonal transport. Our results support the 
use of voluntary exercise and recombinant GDNF to complement other therapy 
treatments used to attenuate neuropathic pain associated with DN. 
 
Exercise is considered an important component for treating diabetes, 
however, it may exacerbate diabetic complications or may produce 
consequences due to existing complications [138]. Before the start of any regular 
physical activity, the potential risks (i.e. foot ulcers, cardiovascular function, etc.) 
needs to be assessed in order to minimize any complications the diabetic patient 
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may experience. Therefore, clinicians and patients must work together to 
maximize exercise-induced benefits while minimizing the adverse events in order 
to obtain a healthier lifestyle and improve the patients quality of life [138]. 
 
4.5.5 Conclusion 
Results obtained from our study, demonstrates the beneficial effects 
voluntary exercise has on reducing mechanical hypersensitivity in diabetic mice. 
The significance of this study has shown the therapeutic effects GDNF has on 
reducing mechanical allodynia associated with DN. Therefore, GDNF and 
molecules in the GDNF signaling pathway are potential therapeutic targets for 
















Discussion and conclusion  
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5.1 Summary and findings 
Among the most debilitating types of chronic pain is peripheral 
neuropathic pain [147], which results from damage to peripheral sensory axons 
[11]. Damage to these axons can occur due to physical trauma, such as nerve 
trauma (via surgery, compression, etc.), or metabolic diseases, such as diabetes 
[11]. These physical and metabolic insults lead to multiple pathophysiological 
changes in both the PNS and CNS [117]. Neuropathic pain is challenging to 
manage. Many pharmacological treatments are available to treat neuropathic 
pain; however, only 40% to 60% of patients obtain partial relief of their pain [148]. 
Therefore, the identification of efficacious non-pharmacologic treatments for 
neuropathic pain, and the development of strategies to prevent neuropathic pain 
are needed to advance the management of this debilitating disease [148]. 
 
Recently, we have shown that forced exercise (via swimming) reduced 
behavioral sensitivity associated with peripheral nerve injury [30]; however, the 
exercise-induced mechanisms were not researched in this study. Numerous 
mechanisms are responsible for peripheral neuropathic pain. In the events 
following peripheral nerve injury, dysfunction of GDNF signaling in the 
nociceptive afferent system contributes to the development and/or maintenance 
of neuropathic pain [72-75]. Several studies have shown that exercise can alter 
GDNF expression in various neuronal and non-neuronal tissues [40, 88-90]. 
Therefore, experiments were conducted in order to determine whether the 
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beneficial effects exercise had on behavioral sensitivity in nerve injured rats were 
due to changes in GDNF levels. 
 
Our results shown in Chapter 2 demonstrated the beneficial effects 
voluntary exercise has on mechanical sensitivity associated with neuropathic 
pain. Both SNI groups developed a marked hypersensitivity to mechanical 
stimulation of the lateral surface of the hindpaw 5 days after surgery. Within the 
first 3 weeks of training, exercise reduced mechanical allodynia and 
hyperalgesia, which lasted up to 110 days. GDNF protein levels in the spinal cord 
increased following nerve injury; however there were no difference in GDNF 
levels between the sedentary and exercised groups at day 110. Therefore, a 
mechanism responsible for the exercise-induced reductions in behavioral 
sensitivity exhibited in rats experiencing neuropathic pain is not likely to involve 
the GDNF pathway and remains to be elucidated. However, this conclusion is 
difficult to propose due to the fact that there were not age matched controls in 
order to determine whether the increases in GDNF levels, which were exhibited 
at day 110, were due to the SNI surgery or age itself. 
 
Several plausible mechanisms exist for analgesia following exercise. 
These mechanisms involve the opioid and non-opioid systems. The most 
commonly tested mechanisms has been exercise-induced release of 
endogenous opioids at either peripheral, spinal, or central sites capable of 
modulating pain [149]. As reviewed by Koltyn (2000), data regarding the 
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exercise-induced analgesia via the opioid system in non-pathological conditions 
are mixed. However, exercise-induced release of endogenous opioids is believed 
to be involved in attenuating behavioral sensitivity associated with chronic 
muscle pain [32]. Non-opioid systems that reduce pain are believed to involve the 
serotonergic pathway, neurotrophin availability, and increases in blood pressure. 
Serotonin modulates pain sensitivity through the descending pain pathways 
[150], through the release of GABA [151]. Recently, Mazzardo-Martins et al. 
(2010) showed that high-intensity extended swimming reduced behavioral 
sensitivity in mice. This reduction in nociception was attenuated by pretreatment 
with rho-chlorophenylalanine methyl ester (PCPA, an inhibitor of serotonin 
synthesis), therefore implicating the involvement of serotonergic pathway in 
exercise-induced analgesia [152]. Numerous studies have shown that aerobic 
exercise can increase neurotrophin expression [31, 36-42]. Neurotrophins have 
been shown to induce analgesia by modulation of the glutamatergic transmission 
and neuropeptide release through both opioid and serotonergic mechanisms 
[126]. Therefore, it is believed that increases in neurotrophins with exercise may 
have analgesic effects. Elevation in blood pressure is believed to be a potential 
mechanism in reducing pain following exercise. As reviewed by Koltyn and 
Umeda (2006), there may be an interaction between exercise, hypoalgesia, and 
blood pressure. During exercise baroreceptors are activated due to increases in 
systolic blood pressure [153]. Research indicates that activation of baroreceptors 
results in CNS inhibition and that stimulation of the baroreceptor are associated 
with decreases in pain perception [154]. Therefore, one or more of these 
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mechanisms may be responsible for the reductions in mechanical sensitivity 
seen in the exercised SNI rats. 
 
Peripheral neuropathic pain can result from axonal damage by metabolic 
diseases, such as diabetes. Type 1diabetes is considered to be a chronic 
immune mediated disease characterized by a selective loss of insulin producing 
β-cells in the pancreatic islets of genetically susceptible subjects [155]. This 
disease imposes a substantial burden on the nervous system, which results in 
peripheral nerve damage that leads to DN [51]. Numerous mechanisms are 
involved in the pathogenesis of DN, which includes reductions in neurotrophic 
support (i.e. GDNF) [156]. Liu et al. (2009) demonstrated that neuropathic 
symptoms in diabetic rats are negatively correlated with the levels of GDNF 
expression. As GDNF expression in the sciatic nerve diminished, neuropathic 
symptoms increased; however, after GDNF gene delivery, these neuropathic 
symptoms were alleviated [54]. Aerobic exercise has been shown to increase 
GDNF in skeletal muscle [88, 90], which is innervated by both sensory and motor 
neurons via the sciatic nerve. Therefore, a series of experiments were conducted 
in order to determine how diabetes affects GDNF protein levels and mRNA 
expression and whether voluntary exercise has any influence in order to 
attenuate or delay the behavioral sensitivity associated with DN. 
 
Our results shown in Chapter 3 and 4 demonstrated that voluntary 
exercise ameliorates mechanical allodynia associated with DN in both rats and 
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mice. One week after STZ-injections, the diabetic groups in both species 
exhibited an increase in mechanical sensitivity. Similar to the SNI study, 
voluntary exercise attenuated mechanical allodynia in both rats and mice within 
the first 3 weeks post STZ-injections, which persisted throughout the remaining 
of the studies. Diabetes duration of 6 weeks significantly reduced GDNF protein 
levels in the spinal cord of mice, however, 8 weeks did not in rats. Six and 8 
weeks of voluntary exercise significantly increased GDNF protein levels in the 
spinal cord of diabetic animals in both mice and rats, respectively. In diabetic 
rats, this increase was greater in the ventral horn of the spinal cord. Among mice, 
voluntary exercise robustly increased GDNF protein levels and mRNA 
expression in the sciatic nerve and gastrocnemius muscle compared to their 
sedentary counterparts, respectively. Among both species, voluntary exercise 
increased mechanical thresholds around the 2 week time period (day 14 for mice 
and day 17 for rats). Our results showed that diabetes did not reduce GDNF 
protein levels in the spinal cord and sciatic nerve two weeks post STZ-injection in 
mice. However, 2 weeks of voluntary exercise increased GDNF levels in the 
sciatic nerve of diabetic mice, which is where the initial behavioral differences 
were seen. 
 
Mechanisms that may mediate GDNF expression include mechanical 
activity, such as exercise. It has been shown that mechanical activity, in the form 
of stretch, positively stimulates trophic factor production in vascular and bladder 
smooth muscle cells [157]. It is believed that increased production and release of 
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growth factors are activated by the protein kinase C signaling pathways through 
an influx of calcium via voltage-gated calcium channels signaling pathways [90, 
158]. Adenosine monophosphate-activated protein kinase (AMPK) may also 
mediate GDNF production. AMPK regulates skeletal muscle transcription and 
phenotype [159]. Exercise or muscle contraction is the most potent activator of 
AMPK in skeletal muscle. Work loads of 60% are sufficient enough to increase 
AMPK activity [160]. In skeletal muscle AMPK acutely increases ATP production. 
In ischemia states, such as diabetes, ATP is broken down into Adenosine [161]. 
Yamagata et al. (2007) demonstrated that adenosine induces and regulates the 
expression of GDNF. Therefore, many factors may play a role in exercise-induce 
gene expression of GDNF. However, it remains unknown how exercise increases 
GDNF expression in skeletal muscle and future studies are needed. 
 
To further investigate the role GDNF plays in attenuating mechanical 
sensitivity associated with DN, diabetic mice received intrathecal injections of 
GDNF for 2 weeks. Our study showed that administration of GDNF for 2 weeks 
prevented the onset of mechanical sensitivity in diabetic mice. Therefore, our 
results support the view that GDNF has potent therapeutic actions in painful DN; 
however, our studies do not provide clear insight as to whether GDNF depletion 
in diabetes is involved in the initiation and maintenance of mechanical allodynia. 
 
It is believed that neurotrophic factor deficiency in diabetes may be due to 
disturbances in axonal transport, which is critical for maintaining normal 
metabolism, physiological activity, and structural integrity of the nerve [53, 91]. 
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GDNF is synthesized and secreted by a number of neuronal and non-neuronal 
tissues [63, 66-69]. To gain some perspective about the source(s) of GDNF in 
the spinal cord and sciatic nerve, we performed nerve ligation studies to 
determine if GDNF protein was transported retrogradely from the gastrocnemius 
muscle. Our results suggest that exercise-induced changes in GDNF are due to 
increases in both anterograde and retrograde levels of transported GDNF, with 
the greatest changes occurring in an anterograde direction. Collectively, these 
results suggest that exercise-induced increases in GDNF expression in the 
gastrocnemius muscle may influence spinal circuitry via retrogradely transport 
and release within the spinal cord. Increased accumulation of GDNF protein 
levels in the ventral horn, which was illustrated in our diabetic exercise rats, leads 
to anterograde axonal transport of GDNF in the sciatic nerve where it is released 
at the axon terminals in the skin and muscle where it could possibly serving as a 
neuromodulator. Therefore, it is possible that these mechanisms represent 
endogenous systems that enable communication between sensory/motor 
neurons and peripheral tissues that respond to exercise. 
 
GDNF has been shown to be a target-derived trophic factor, in which 
GDNF may be obtained from the target and transported retrogradely to the cell 
body (neurotrophic hypothesis), where it can exert its trophic effects [162]. In our 
study, we demonstrated that voluntary exercise increases GDNF expression in 
the gastrocnemius muscle and retrograde axonal transport. Therefore, another 
possible mechanism for reducing in mechanical allodynia in our exercised 
207 
 
diabetic animals may be due to retrograde axonal transport of GDNF from the 
gastrocnemius muscle to the dorsal horn where it inhibit pronociceptive peptides 
[76]. 
 
Microglia, are a major immune cell population in the CNS [163]. They 
represent 5% to 10% of glia in the CNS and are considered resident 
macrophages [147]. Microglia, are inactive in healthy adult CNS, and become 
activated in acute and chronic neurodegenerative diseases [163]. After CNS 
injury, microglia become activated and they produce cytotoxic inflammatory 
mediators, such as nitric oxide (NO), reactive oxygen species (ROS), tumor 
necrosis factor-a (TNF-a), and interleukin-1 beta (IL-1b). It is believed that this 
action plays a crucial role in triggering secondary tissue damage, which in turn 
leads to the progression of CNS diseases. Alternatively, activated microglia also 
play a role in phagocytotic activities, such as removing neural cell fragments and 
myelin debris, via the production of neurotrophic factors. This is beneficial to 
neuronal survival in the damaged CNS [163]. It has been established that 
microglia express GDNF receptor complex GFRα and Ret [164, 165]. Chang et 
al. (2006) demonstrated that GDNF positively regulates microglial activities, such 
as phagocytosis and the upregulation of adhesion molecules via the MAPK 
signaling pathway. Therefore, GDNF administration may have a protective effect 
on neurons by modulating microglial activities and increasing adhesion 
molecules to aid in axonal regeneration in order to return the neuron to its normal 
function. Collectively, there are many potential mechanisms that may exist on 
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how GDNF regulates nociceptive inputs both peripherally and centrally. Whether, 
pain modulation via GDNF occurs in the periphery or in the spinal cord remains 
to be seen, as a result, more research is clearly warranted. 
 
5.2 Clinical implications 
Treating symptoms associated with neuropathic pain continues to be a 
clinical challenge due to the variability and complexity of the disease. Presently, 
therapeutic options are largely limited to pharmacological treatments [119], which 
results in limited success [3]. Therefore, we explored the use of voluntary 
exercise as potential non-pharmacological therapy to treat neuropathic pain 
symptoms. Collectively, our results support the use of voluntary exercise to 
complement current therapy treatments used to attenuate behavioral sensitivity 
associated with neuropathic pain. Evidence supporting exercise for treating 
neuropathic pain is limited; however given its presumed safety, exercise should 
be considered whenever appropriate [131]. Given the diversity of neuropathic 
pain mechanisms, patient responses, and other potential disease that may affect 
the patient’s ability to exercise, such as cardiovascular disease, treatments must 
be individualized. 
 
Exercise has long been recognized as a part of therapy in the 
management of diabetes. While exercise may be a cost effective treatment, it 
may exacerbate complications or produce consequences due to existing 
complications associate with diabetes [138]. Prior to starting an exercise program 
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patients with diabetes should be evaluated in order to prevent exacerbation of 
macro and micro vascular complications. Diabetic patients experiencing 
peripheral neuropathy should only consider exercises they can tolerate without 
intensifying their painful symptoms. Most importantly, all patients should monitor 
their blood glucose levels before, during, and after all bouts of exercise. For 
diabetic patients, the overall benefits of exercise are clearly significant, such as 
preventing and reducing painful DN [60, 61]. Therefore, clinicians and patients 
must work together to maximize exercise-induced benefits while minimizing the 
adverse events in order to obtain a healthier lifestyle and improve the patients 
overall quality of life [138]. 
 
5.3 Future directions 
As described above exercise-induced analgesia involves several 
mechanisms. In the SNI study, future studies would explore the potential 
exercise-induced analgesic mechanisms described above. In diabetic animals 
one possible mechanism involves increases in GDNF both centrally and 
peripherally. To further investigate the role GDNF plays in attenuating 
mechanical allodynia in diabetic animals, a GDNF knockout model should to be 
explored. Homozygous GDNF mice (GDNF-/-) with the deletion of the GDNF 
gene die with 1 to 1.5 days after birth, however the heterozygous GDNF mice 
(GDNF+/-) with the deletion of one allele of the GDNF gene have been shown to 
survive at least for 14 weeks [166, 167]. Similar to the wild type mice (GDNF+/+), 
GDNF+/- mice displayed normal neuronal innervations of the intestine [168], along 
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with no deficits in facial motor neurons, dopaminergic neurons and fiber density, 
and noradrenergic neurons [169]. Therefore, GDNF+/- mice are a useful model for 
studying the effects of endogenous GDNF [167]. With this animal model we may 
be able to determine whether exercise-induced increases in GDNF is a 
mechanism involved in reducing mechanical allodynia in diabetic animals or 
whether other exercise-induced mechanism described above are involved. 
 
The goal of our research is to enhance therapy treatments in humans by 
being able to translate our bench top findings to bedside practices. Our studies 
showed that the mechanical sensitivity and GDNF levels did not correlate with 
the total amount of exercise the animals participated in. To make our findings 
translational we need to determine the duration of exercise our animals need to 
participate in order to attenuate their mechanical sensitivity. Humans must 
exercise at a workload of greater than 70% of their maximal aerobic capacity 
[125]. Therefore, experiments are needed exploring whether exercising animals 
at a workload greater than 70% is sufficient enough to induce analgesia along 
with the mechanism that may be involved. 
 
5.4 Conclusion 
The body of work presented in this dissertation extends the current 
knowledge of the current pain literature by examining the use of voluntary 
exercise as a non-pharmacological therapy for treating neuropathic pain. The 
findings of our studies demonstrate the beneficial effects exercise has on 
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attenuating neuropathic pain. Our studies allude to potential mechanisms that 
result in analgesia following extended exercise. Future animal and human 
studies are greatly needed in order to determine the biological mechanisms that 
integrate exercise and pain, and future clinical studies are needed to determine 
the importance of timing and intensity of exercise in terms of injury onset and 
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